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5Abstract
Accumulating wealth in the western world has led to an increase in chronic health 
problems such as obesity. Obesity is often associated with abnormal metabolic 
function, resulting in increased glucose, cholesterol and triglyceride levels in the blood. 
Development of cardiovascular diseases and type 2 diabetes is often observed as 
a result of obesity. Disturbed lipid metabolism is one of the major processes altered 
with obesity. Investigation of  the fundamental molecular mechanisms involved in 
lipid metabolism may be beneficial to the prevention and treatment of this disease. 
One of the proteins involved in the regulation of the lipid metabolism is the nuclear 
receptor named Peroxisome Proliferator-Activated Receptor alpha (PPARα). PPARα 
resides in the nucleus and functions as an inducible transcription factor, which upon 
binding of fatty acid binds to specific regions within the DNA.  As a consequence, the 
transcription of several genes that encode for enzymes and other proteins that are 
responsible for the catabolism of fatty acids and energy homeostasis is increased.
In this thesis, several aspects related to the mechanism of PPARα function are 
described. First it was investigated what proteins physically interact with PPARα 
and may thus be necessary for proper transcription of target genes. Secondly it was 
investigated what genomic locations PPARα is bound to and if the binding results 
in enhanced expression of genes located near these binding locations. Thirdly, the 
predictability of PPARα DNA binding based on specific DNA sequences was studied. 
Finally, a comparison was made between PPARα regulated genes in primary human 
hepatocytes and the human liver cell line HepG2.
The presence of PPARα alone is not sufficient to induce the expression of a target 
gene. Additional proteins, coactivators,  have to interact with PPARα to form a larger 
protein complex that stimulates gene expression. Currently, it is not completely 
known which coregulator proteins are involved in PPARα-mediated gene regulation. 
With the use of immunoprecipitation and mass spectrometry, it is possible to isolate 
protein complexes and identify protein interactions with a tagged protein. Those 
techniques were used to identify proteins that interact with PPARα, resulting in 
the identification of several proteins that may play a role in the regulation of gene 
expression by PPARα. 
To investigate which genomic locations are bound by PPARα after ligand activation, 
the ChIP-Chip technology was used. This technique combines chromatin 
immunprecipitation with specialized microarrays called DNA tiling arrays . With the 
use of ChIP it is possible to isolate DNA fragments of approximately 1000 base pairs 
that are bound by PPARα. By hybridizing the isolated DNA fragments to a promoter 
6tiling microarray, it is possible to  create a profile of PPARα binding across the whole 
genome. Over 4000 DNA regions were identified using this approach, including 
binding regions near genes that were previously described to be regulated by PPARα 
The identified genes located near PPARα binding regions were compared with gene 
expression data. PPARα binding regions near genes that were transcriptionally 
downregulated were found to be enriched for a binding motif for the STAT transcription 
factors. Binding of STAT3 and STAT1 to these regions was shown to be reduced 
upon PPARα activation. Interestingly, STATs are involved in inflammatory processes 
that are known to be inhibited by PPARα activation and were previously shown to 
be inhibited by PPARγ. Accordingly, it can be hypothesized that down-regulation of 
gene expression by PPARα ligands is partially mediated by interfering with binding 
of STAT3 and STAT1 to the DNA. Similarly, PPARα binding regions near genes that 
were transcriptionally upregulated were found to be enriched for a binding motif for 
TBP and C/EBPα. In addition, important cross-talk between PPARα and SREBP was 
found with respect to upregulation of gene expression. Possibly, these combinations 
of transcription factors play an important role in PPARα-mediated gene regulation.
To examine the relation between DNA binding by PPARα, changes in gene 
expression, and predicted PPARα  DNA binding, we compared various data sets 
via a systems biology type of analysis. This comparison clearly showed that the 
number of locations where PPARα is able to bind greatly exceeds the number of 
genes that are transcriptionally regulated. This indicates that in many cases DNA 
binding by PPARα does not result in changes in expression of genes located nearest 
to the binding location. Possibly, PPARα binding has another unknown function at 
those locations. It appeared also from this comparison  that a prediction of PPARα 
binding on the DNA on the basis of sequence alone did not give an enrichment 
of PPARα  binding sites in the identified ChIP-Chip regions compared to control 
promotor regions.  However, one of the prediction algorithms did give an enrichment 
on basis of sequence when only considering PPARα binding locations associated 
with upregulated genes. The latter method may be useful for identification of new 
genes that are regulated by PPARα. 
Finally, a comparison was made between the gene expression patterns after PPARα 
activation in the human liver cell line HepG2 and human primary hepatocytes. 
It appears that the HepG2 cell line poorly reflects the known PPARα function in 
comparison to primary hepatocytes. Several known PPARα target genes are induced 
by PPARα agonist in primary hepatocytes but are unresponsive in the HepG2 cell 
line. Therefore, it is recommended to exercise caution in the interpretation of results 
using HepG2 cells and if possible select primary hepatocytes. However, since an 
7alternative human liver cell line is not widely available, HepG2 still remains the best 
model for several applications.
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Chapter 1
Throughout the body concentrations of small lipophilic compounds such as fatty 
acids, cholesterol, fat-soluble vitamins and hormones fluctuate regularly as a 
response to dietary intake or increased endogenously synthesis of steroid hormones. 
To respond to the changes in concentration of these small lipophilic compounds and 
their derivatives, a biological system exists to translate these changes to alterations 
of gene expression and maintain homeostasis. A large number of ligand inducible 
transcription factors, more specifically the superfamily of nuclear receptors (NR) are 
responsible for these changes in gene expression. Nuclear receptors can recognize 
changes in concentration of a particular compound or its metabolite and respond by 
activating transcription of a specific set of genes. in general the genes activated are 
responsible for clearance of the activating compound either via a feedback loop by 
reducing genes involved in the synthesis of the compound or via a feed forward loop 
that increase the catabolism of the compound (1). 
In the 80s the first nuclear receptor, the glucocorticoid receptor (GR) was cloned (2). 
The cloning of several other human nuclear receptors quickly followed including the 
estrogen receptor (ER) (3), Progesterone Receptor (PR) (4), Androgen Receptor 
(AR) (5), Retinoid X Receptor (RXR) (6) and Peroxisome Proliferator-Activated 
Receptor (PPAR) (7). Currently 49 nuclear receptors have been identified. Among 
them are several nuclear receptors for which no regulatory ligand has been identified 
and are referred to as “orphan receptors”. Nuclear receptors are classified based on 
conservation between of two well conserved protein domains (DNA-binding domain 
and ligand binding domain). Using this approach, six subfamilies could be identified. 
In addition a separate group was formed that contains nuclear receptor subtypes 
that only have one of the two conserved domains present (8). When grouping the 
nuclear receptors based on physiology instead of conservation, two main groups 
were identified. The first group contained nuclear receptors involved in reproduction, 
development and growth which include the endocrine steroid receptors, such as the 
androgen receptor and estrogen receptor. The second cluster is made up by nuclear 
receptors involved in nutrient uptake, metabolism and excretion (9). Receptors within 
this group are activated by dietary nutrients or their metabolic products and include 
the PPARs. 
Peroxisome proliferator- activated receptors
Peroxisome proliferator-activated receptors (PPARs) are classified in nuclear 
receptor group 1 subgroup C. Three different PPAR isotypes have been identified 
which are highly conserved between species: PPARα (NR1C1), PPARβ/σ (NR1C2) 
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and PPARγ (NR1C3). Each isotype plays an important role in the regulation of 
numerous biological processes, including lipid metabolism, adipocyte differentiation, 
cell proliferation and inflammation (10).
PPARα is widely expressed with highest expression levels found in tissues with high 
energy demand such as liver, muscle and kidney (Figure 1) (11-13). In those tissues 
PPARα governs the expression of various genes involved in fatty acid catabolism, 
gluconeogenesis, lipogenesis, cholesterol metabolism and lipoprotein metabolism 
(14-16). In addition, PPARα has anti-inflammatory properties by suppressing the 
expression of pro-inflammatory genes such as interleukin-6 (IL-6), C-reactive 
protein (CRP) and TNF-α (17-20). At first, PPARα knock out (KO) experiments in 
mice revealed no essential role for PPARα in embryonic development and adult 
mice appeared healthy (21). However, PPARα KO mice showed increased levels 
of circulating triglycerides (TG), cholesterol and develop hepatosteatosis (22,23).  A 
more severe phenotype is observed in PPARα deficient mice during fasting. A strong 
increase in circulating fatty acids, hepatic and cardiac lipid accumulation as well as 
hypoglycemia is observed in PPARα KO mice as a result from a failed response to 
catabolize fatty acids released from the adipose tissue (24-26). Furthermore the 
absence of PPARα impaired wound healing (27)  and prolonged inflammation (28).
The PPARβ/σ isotype is expressed ubiquitously and often at higher levels than 
PPARα (Figure 1). The highest expression is observed in small intestine, heart, and 
skin tissue (9,12,29). Compared to PPARα much less is known about PPARβ/σ. So 
far PPARβ/σ has been linked to the regulation of glucose homeostasis, fatty acid 
metabolism, wound healing, and inflammation (30-33). In contrast to PPARα KO 
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Figure 1: Gene expression of the three PPAR subtypes in various human tissues
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mice, PPARβ/σ deficient mice show high embryonic mortality. PPARβ/σ KO mice 
displayed increased VLDL production, reduced fatty acid oxidation in the heart as 
well as cardiac hypertrophy and dilated cardiomyopathy (34-36). Similar to PPARα 
and PPARγ, recent studies suggest that PPARβ/σ is also involved in regulation 
of inflammatory pathways. The main body of evidence points to a general anti-
inflammatory action of PPARβ/σ that can be observed in a variety of tissues (37). A 
number of mechanisms have been put forward that underlie the anti-inflammatory 
effect of PPARβ/σ but according to one mechanism, PPARβ/σ activation leads to 
dissociation of PPARβ/σ-associated corepressors that subsequently contribute to 
the reduction in expression of inflammatory genes  (38). 
PPARγ likely represents the most extensively studied PPAR isotype. Four different 
splice variants for PPARγ have been identified: PPARγ1, PPARγ2 (39),  PPARγ3 
(40) and , PPARγ4 (41). The  most abundant splice variants PPARγ1 and PPARγ2 
are predominantly expressed in adipose tissue, with PPARγ2 almost exclusively 
expressed in this tissue (Figure 1) (42). Additionally, PPARγ is well expressed in 
lung, most likely because of the abundance of alveolar macrophages. PPARγ was 
identified as a crucial regulator of adipose cell differentiation and lipid storage (43). 
In addition to its function in adipose tissue development, PPAR-γ has, similar to 
PPARα and PPARβ/σ, a role in  monocytes and macrophages, where it is involved 
in the regulation of inflammatory proteins TNF-α, IL-6, and iNOS (44), as well as in 
lipid uptake (45). As whole body PPARγ KO mice are not viable, tissue specific knock 
outs were created to investigate its function in several tissues. Specific deletion in 
adipose tissue of PPARγ proved the critical role of PPARγ in adipose differentiation 
and adipose survival (46,47).  Furthermore, deletion of PPARγ in fat and liver caused 
insulin resistance (48).
PPAR protein structure
The primary structure of PPARs conforms to the general structural organization of 
members of the nuclear receptor superfamily. At the N-terminus PPARs and numerous 
other nuclear receptors contain a so called A/B region that harbors a transcriptional 
activation function (AF-1). This highly divergent region has been shown to mediate 
transcriptional activation of nuclear receptors independent of ligand binding. 
Phosphorylation of specific amino acid residues within this region can alter ligand-
dependent as well as ligand-independent activation by the nuclear receptor. In the 
case of PPARα,  two serine residues in the A/B region can be phosphorylated via the 
ERK-MAPK pathway leading to enhanced basal and ligand-induced transcriptional 
activity (49). In contrast, the PPARγ isoform shows impaired transcriptional activity in 
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adipocytes upon MAPK-mediated phosphorylation within the A/B region (50).   
The most conserved domain among nuclear receptors is the DNA-binding domain 
(DBD), which is also referred to as C-domain. This domain contains two zinc fingers 
as well as a C-terminal extension. The DBD folds into a globular structure composed 
of two α-helixes that are able to make contact with the major groove of DNA. The 
“P-Box” located at the base of the first zinc finger is responsible for recognition of 
specific core DNA sequences. The D domain is located between the DBD and the 
ligand binding domain (LBD). This domain is less conserved and functions as a 
hinge between the DBD and the LBD. Finally, the C-terminal ligand binding domain 
(LBD or E-domain) contains a ligand-dependent activation function (AF-2). The LBD 
crystal structure of PPARγ revealed 13 α-helixes and 4 β-sheets that fold into a 
globular structure containing a large hydrophobic T-shaped cavity that is able to bind 
ligands (51-53). Differences in amino acid composition in the regions forming the 
hydrophobic cavity are responsible differences in ligand binding properties between 
PPAR isotypes. Besides binding of ligands, the LBD is involved in dimerization as well 
as providing a platform for regulatory proteins involved in the initiation of transcription 
such as coactivators. Stabilization of the highly dynamic helix 12 (H12) of the LBD 
upon ligand binding or via a ligand independent manner promotes recruitment of 
coactivator complexes to the LBD, resulting in increased transactivation (51,54-56). 
The flexible hinge region for a long time precluded the assembly of crystals of intact 
nuclear receptors. As a consequence, structural insight into how multiple domains 
cooperate to modulate receptor properties was lacking. Recently, the structures of 
intact PPAR-gamma and RXR-alpha as a heterodimer bound to DNA, ligands and 
coactivator peptides was presented. It was shown that PPAR-gamma and RXR-
alpha form a non-symmetric complex, allowing the ligand-binding domain (LBD) of 
PPAR-gamma to contact multiple domains in both proteins, including both DNA-
binding domains (DBDs), leading to enhanced response-element binding (57)
PPAR ligands
Consistent with the role of PPARs in lipid metabolism, PPARs are induced by 
naturally occurring long-chain fatty acids (LCFA) and LCFA-CoA  (58-60). Besides 
unmodified fatty acids, PPARs can be induced by various fatty-acid derived 
compounds. Arachidonic acid can be metabolized by 5-lipoxygenases to produce 
the strong chemo-attractant leucotriene B4 (LTB4), which is able to bind and 
activate PPARα (61). The eicosanoids hydroxyeicosatetraenoic acids (HETEs) and 
hydroxyoctadecadienoic acid (HODEs) are produced by 8-12/15-lipoxygenases. 
HETEs bind to the LBD of both PPARα and PPARγ, whereas HODEs bind specifically 
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to PPARγ (60,62,63). In a similar fashion,  arachidonic acid can be metabolized 
by COX enzymes in combination with a tissue-specific PG synthase/isomerase to 
create the compounds that can bind PPARs such as PGI2,  PGA1/2 and 15dPGJ2 
(63-66). Finally, arachidonic acid and linoleic acid  can alternatively be converted by 
the CYP member CYP4A/epoxigenase to produce HETEs (67) as well as the strong 
PPARα agonists hydroxyl-epoxyeicosatrienoic acids (HEETs) (60,68).
Since PPARs play key roles in metabolism as well as possess anti-inflammatory 
properties, they are attractive pharmaceutical targets for many metabolic disorders. 
Synthetically produced fibrates specifically bind to PPARα actually had been on the 
market for several years before they were identified as a PPARα ligand. Fibrates 
effectively ameliorate dyslipidemia by stimulating clearance of triglyceride-rich 
lipoproteins and raising HDL levels (69). Similarly, synthetic PPARβ/σ ligands have 
been shown to be effective against insulin resistance, obesity and dyslipidemia (70), 
at least in animal models. PPARγ represents the most important therapeutic target 
as it serves as the molecular target of the thiazolidinedione class of drugs, which 
include rosiglitazone and pioglitazone.  Thiazolidinedione stimulate lipid uptake in 
the adipose tissue and have glucose-lowering properties by improving lipid and 
glucose homeostasis (71). Accordingly, they are widely prescribed for the treatment 
of type 2 diabetes.
Molecular mechanism
Nuclear receptors regulate transcription of target genes by binding to specific 
DNA sequences named hormone response elements (HRE) present either in the 
promotor region or located more distally relative to the target gene (72,73). Most 
nuclear receptors recognize a specific core HRE motif composed of 6 bases. While 
some receptors bind such hexameric elements as a monomer, the majority of 
nuclear receptors bind as a homo- or heterodimer to two repetitive copies of the 
hexameric motif. HRE recognized by homo- or heterodimers can be constructed by 
two hexameric half sites that are configured as an inverted repeat, everted repeat 
or as a direct repeat (DR). Furthermore, the spacing between the two half sites of 
the element is an important characteristic of a HRE. Although the type of HRE is 
important for conferring specificity to the interaction between PPARs and the DNA, 
several nuclear receptors can bind to a variety of different HREs. For instance, FXR 
can bind to an IR-1 (inverted repeat with a 1 bp spacer), an ER-8 (everted repeat 
with an 8 bp spacer), and a DR-1 (direct repeat with a 1 bp spacer) (74-77). Typically, 
steroid receptors form homodimers and have a preference for inverted repeat 
response elements. In contrast, many non-steroid receptors form heterodimers with 
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the promiscuous nuclear receptor RXR. Although heterodimerization with RXR is 
preferred, some receptors such as the vitamin D receptor (VDR) and RXR itself can 
form homodimers at higher concentrations.  However,  the transcriptional efficiency 
as well as DNA binding is significantly reduced and accordingly the physiological 
relevance remains uncertain (78-80).  
PPARs bind to DNA as a heterodimer with its obligatory partner RXR and recognize 
HREs referred to as PPAR responsive elements (Figure 2) (PPREs) (81). The 
classical consensus PPRE consists of a direct repeat of the hexameric sequence 
AGGTCA separated by one spacer nucleotide (DR1).  PPARs have been shown 
to bind to the 5’ half site of the PPRE, whereas RXR binds to the 3’ half site (82). 
The 3’ half site is the most conserved half site and RXR binding to this site is of 
great importance for proper binding of PPARγ/RXR heterodimers to PPREs (83), 
while the 5’ half site allows for more sequence flexibility. At the same time, the three 
nucleotides upstream of the 5’ half site were shown to be more important for DNA 
binding and gene activation then the three nucleotides downstream of the 3’ half site 
(84). Indeed, the flanking region of the 5’ prime half site of a PPRE was reported 
to be an important discriminatory factor in PPAR subtype recognition (85). Recent 
studies using chromatin immunoprecipitation (ChIP) in combination with genomic 
tilling microarrays or sequencing (ChIP-chip or ChIP-Seq) have provided important 
new information on the requirements for DNA-binding by PPARs and other nuclear 
PPRE
TATA box Target gene
Pol II protein 
complex
PPARα RXRα
PPARα 
agonist
Coactivator 
protein complex
Figure 2: PPARα mediated gene activation. Upon PPARα ligand binding, the PPARα/RXR heterodimer 
located at a PPAR response element recruits a coactivator protein complex that contains or recruits 
histone acetylase activity and mediates the formation of a bridge between PPARα/RXR and the basal 
transcriptional polymerase II protein complex which will initiate the transcription of a PPARα target gene.
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receptors. These studies revealed binding of PPARγ to more than 5000 binding sites 
across the whole genome (84,86). Another study using ChIP-PET identified over 
7000 binding sites in vivo (87). Thus, the number of PPARγ binding sites on the DNA 
vastly exceeds the number of transcriptionally regulated genes, which implies that 
PPARs may bind to DNA without regulating a closely located gene. These findings 
are in agreement with the “scanning model” proposed for PPARs, which states that 
PPARs scan the genome and transiently bind to PPRE-like sequences without 
inducing any transcription. According to this model, PPARs only start transcription 
upon binding to a bona fide PPRE. What separates a bona fide PPRE from a PPRE 
look-alike remains to be further investigated (88). It is also possible that in vivo 
several PPAR binding sites conspire in the regulation of a single gene. However, 
proper tools are lacking to address these issues experimentally. 
It is important to realize that many of the sites identified by ChIP-chip or ChIP-seq do 
not contain a PPRE motif. Looping, protein-protein interactions as well as assisted 
binding via a nearby factor or a modified coactivator are proposed explanations 
for the isolation of non-PPRE containing sites (84). Another interesting finding that 
emerged from Chip-seq was that PPARγ-activated genes show an enrichment of 
modules consisting of a PPRE-like motif together with a C/EBP binding element 
(84,86). A similar enrichment of a TF module was shown for the estrogen receptor 
(ER), which clustered together with forkhead, Oct1 and C/EBP motifs (89), and for 
the androgen and glucocorticoid receptor (90,91). These ChIP-chip studies reveal 
a complex interplay between nuclear receptors and other TFs. Full activation of 
gene transcription by the DNA-bound PPAR-RXR complex is ultimately dependent 
on the formation of a larger transcription initiation protein complex, including RNA 
polymerase II, via recruitment of a number of co-activator proteins (88).
PPAR cofactors
Several cofactors have been identified that participate in the regulation of DNA 
transcription by PPARs. Cofactors can be separated into coactivators and 
corepressors. Coactivators can directly bind to the nuclear receptors, mostly in 
response to binding of a ligand and are involved in the activation of a PPAR target 
gene. In addition, coactivator-associated proteins, which do not directly bind the 
receptor but associate with a coactivator,  may play an important role in PPAR 
activation (Figure 2). Corepressors are also able to directly bind to the receptor but 
inhibit transcription of a target gene. Most likely, all cofactors that are able to associate 
with PPAR are not exclusively used by PPARs but are involved in the transcriptional 
regulation by various other nuclear receptors as well (92). Coactivators can interact 
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directly with a nuclear receptor via the highly conserved LXXLL domain. This domain 
is referred to as the nuclear receptor box (NR box) (93,94). The number of LXXLL 
motifs varies between the coactivators. Differential use of the available LXXLL motifs 
by coactivators as well differences in amino acids flanking the LXXLL motif account 
for binding specificity by nuclear receptors (95). Structure X-ray crystallographic 
analysis of the LBD of nuclear receptors revealed that the LXXLL domain adopts 
a α-helix structure that can bind to the AF-2 domain of the nuclear receptor. The 
positioning of the ligand-stabilized helix 12 in the LBD  together with helix 3, 4 and 5 
provides the interface to which the NR box can bind (53,96). 
Relaxed transcriptionally active DNA is referred to as euchromatin, and is 
characterized by acetylated histones. Histone acetylation is catalyzed by several 
histone acetyltransferases, which transfer the acetyl group from Acetyl-CoA to 
histone H1, H2, H3 and H4, resulting in opening of the nucleosomes. Whereas 
histone acetylation is almost exclusively associated with transcriptionally active 
genomic locations, histone methylation is associated with either transcriptional 
repression or activation, depending on the amino acid methylated. For instance, 
methylation of Lysine 4 (K4) of histone 3 (H3) is associated with active euchromatin 
domains. In contrast, methylation of Lysine 9 of histone 3 is associated with packed 
inactive heterochromatin (97,98). 
Cofactors can be classified roughly into coactivators that posses chromatin 
modifying enzymatic activity and coactivators that lack such enzyme activity. 
Several recruited coactivators upon ligand binding to PPAR function as chromatin 
modifying enzymes, including CBP, p300, and SRC-1/2/3. These coactivators 
contain histone acetyltransferase (HAT) activity. The coactivators PGC1α and 
PGC1β do not have any chromatin modifying activities themselves, but they are 
able to recruit other coactivator-(associated) proteins. PGC1α physically interacts 
with the acetyltransferase p300 (99) as well as BAF60a, which is a subunit of the 
nucleosome modifying SWI/SNF complex (100). PGC1α deficient mice experiments 
showed reduced expression of mitochondrial genes and a impaired response to 
cold exposure and starvation as well as dysfunctional muscles and hepatic steatosis 
(101,102). Surprisingly, fasting induced expression of several PPARα regulated 
genes was not affected in PGC1α deficient mice, suggesting PPARα mediated 
expression is not exclusively dependent on PGC1α interaction (101). It is unknown 
how these genes are regulated in the absence of PGC1α, but it is conceivable that 
other coactivators such as PGC1β may compensate for the absence of PGC1α, 
which would point to some sort of functional redundancy. Coactivator associated 
proteins that were identified to play a part in the protein complex responsible for 
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PPAR gene activation  include CARM1 (PRMT4) and PIMT. Both these proteins 
do not directly associate with PPARs, but are recruited by other PPAR interacting 
coactivators (103). The arginine methyltransferase, CARM1, physically interacts 
with the coactivators p300/CBP and SRC2 (104,105). Via this interaction CARM1 
is able to modify Histone 3 by methylation of arginine 17. CARM1 presence in the 
coactivation protein complex was shown to be important for coactivating nuclear 
receptors ER, TR, AR and FXR (106,107), but also other transcription factor such 
as β-catenin, p53 and NF-κB (108). Interestingly CARM1 knockout mice showed 
reduced ability for differentiation towards mature adipocytes. Additional  experiments 
showed that CARM1 is an important coactivator for PPARγ, which regulates adipocyte 
differentiation (109). In addition to its histone methylation activity, CARM1 can also 
methylate coactivators, including the CBP and p300 coactivators. Methylation of 
CBP for example is important for strong coactivation of the estrogen receptor (110). 
PIMT, another methytransferase, interacts with the PPAR binding coactivator PRIP 
and enhances  its coactivator function. It can bind RNA, suggesting a functional role 
as a RNA methyltransferase in PPAR mediated gene activation (111). Additionally, 
PIMT also interacts with CBP/p300 as well as TRAP220 and may function as a 
bridge between CBP/p300 and the mediator complex (112).
In addition to coactivators that contain enzymatic activities to remodel chromatin, a 
second group of coactivators that do not possess any enzymatic activity, such as the 
previously described PGC1α and BAF60c have been identified. These coactivators 
function as a docking space for protein complexes containing chromatin remodeling 
enzymatic activities or are involved in the formation of a large protein complex called 
the TRAP/DRIP/ARC Mediator complex. The mediator complex is a large protein 
complex of approximately 2 MDa composed of at least 30 subunits (113). One of 
the subunits, MED1/TRAP220 was identified to interact with PPAR and RXR in a 
ligand-dependent manner (114).  TRAP220 contains two LXXLL motifs (NR box 1 
and 2)  that can interact with nuclear receptors. In case for PPARγ-RXR, binding of 
TRAP220 NR box 1 is selectively required for interaction (115). Deletion of TRAP220 
is embyonically lethal and leads to similar abnormal development of organs and 
placental vasculature as observed in PPARγ deficient mice (116,117). Also, specific 
deletion of TRAP220 in liver cells almost completely abolished ligand dependent 
PPARα gene activation (118), clearly indicating the importance of this protein 
complex in PPAR mediated gene activation. Functionally, the mediator complex 
act as a bridge between PPARs and the basal transcription machinery.  Preformed 
mediator-polymerase II protein complexes have been purified (119), but enhanced 
recruitment of the mediator complex to the polymerase II complex located at the 
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transcription start site (TSS) has been observed as well (120). These two findings 
suggests that polymerase II is either recruited to the TSS directly in a preformed 
complex with the mediator or is the mediator complex is additionally recruited to 
polymerase II located at the TSS upon binding of a nuclear receptor. 
Via the combination of coactivators responsible for chromatin remodeling and 
looping to the basal transcriptional machinery at the transcription start site (TSS), 
initiation of transcription of a target gene can be achieved (Figure 2). Recently, it 
was shown that this dynamic process has a cyclical nature at the promoter region 
of the PPAR target gene PDK4. One such cycle lasts approximately 60 minutes 
and consists of an initiation phase where PPARβ/δ binds together with the histone 
modifying coactivators CBP and CARM1, followed by an activation phase where 
PPARβ/δ loops to polymerase II  at the TSS via mediating proteins and production 
of mRNA is initiated. In a final step, corepressors are recruited that can deacetylate 
histones and deactivates the whole transcriptional process (121).
Outline thesis
Mechanisms involved in transcriptional activation can be studied in several ways. 
Physical interaction between transcription factors, such as the interaction between 
PPARα and its coregulators (Figure 2) can be detected by co-immunoprecipitation 
or fluorescence spectroscopy using tagged proteins. Having a tagged protein 
available, the co-immunoprecipitation approach can be adapted to identify novel 
interacting proteins by mass spectrometry. Besides protein-protein interactions, 
interactions between proteins and the DNA play an vital part in transcriptional 
regulation. For instance, without the interaction of the PPARα/RXR heterodimer with 
DNA, no transcription can be initiated (Figure 2). To identify DNA fragments that 
are involved in such DNA-protein interactions, ChIP-Chip or ChIP-seq are powerful 
tools. ChIP-Chip  combines the isolation of proteins physically bound to the DNA 
via immunoprecipitation with high throughput tiling microarray technology. With this 
technique all protein-DNA interactions can be identified either on a whole genome 
scale or at all promoter regions, depending on the ChIP set used. To further verify 
identified protein-protein or protein- DNA interactions, introduced modifications of the 
identified proteins or DNA regions in combination with possibly functional alteration 
in the overall transcriptional activity, may validate such interactions. As a result of 
successful transcription, mRNA levels of target proteins change (Figure 2), which 
in turn can be measured on a global scale with expression microarrays. In most 
cases these changes in mRNA are translated into changes of protein levels, which 
may lead to improved adaptation or result in a change in cellular environment. For 
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instance, a PPARα mediated  increase of enzymes involved in β-oxidation can occur 
as a response to increased fatty acids level. 
 
In this thesis, the molecular mechanisms of PPARα action was investigated via a 
number of different approaches. Physical coregulator binding to the PPARα receptor 
was investigated using a proteomics approach (Chapter 2).  Several interacting 
proteins were found that may play a role in regulating  PPARα-mediated gene 
transcription. To investigate the whole genome binding of PPARα in gene promoters, 
a genome-wide binding profile was made of activated PPARα in human hepatoma 
HepG2 cells using ChIP-chip technology (Chapter 3). Over 4000 DNA regions were 
identified that interacted with PPARα, including several binding regions located near 
known PPARα target genes. Furthermore, the data suggests interplay between 
PPARα and STAT transcription factors in transcriptional repression. Similarly, 
interplay between PPARα and TBP, PPARα and C/EBPα, and PPARα and SREBP 
may occur in transcriptional activation. To explore the relation between predicted 
PPARα DNA binding, actual in vivo DNA binding and transcriptional gene activation, 
In vivo PPARα binding was compared with predicted PPARα DNA binding and 
changes in mRNA. The number of predicted PPARα DNA binding sites and in vivo 
DNA binding regions each significantly exceeded the number of transcriptionally 
regulated genes, indicating that DNA binding alone is insufficient for transcriptional 
initiation. Furthermore,we identified various transcription factor binding site modules 
coupled to specific PPARα binding patterns and patterns of gene regulation that may 
play a role in PPARα-dependent gene regulation (Chapter 5). Finally, a comparative 
analysis was carried out between the PPARα-induced transcriptome in HepG2 cells 
and the PPARα-induced transcriptome in primary hepatocytes to investigate the 
suitability of HepG2 cells in PPARα research (Chapter 4). It was shown that HepG2 
cells relatively poorly reflect the established function of PPARα in lipid metabolism 
in contrast to primary human hepatocytes. Accordingly, caution should be exercised 
in the interpretation of data obtained using HepG2 cells, although, the lack of a 
suitable and readily available alternative human liver cell model still makes HepG2 
the preferred choice as a model for human hepactocytes. Overall this thesis covers 
several parts of the molecular mechanisms involved in PPARα action and may 
contribute to better understanding of PPARα-mediated gene regulation.
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Abstract
The nuclear receptor Peroxisome Proliferator-Activated Receptors alpha (PPARα) 
is an important transcriptional regulator of genes involved  in lipid metabolism and 
inflammation. Transcriptional activation by PPARα requires interactions between 
PPARα and coregulatory proteins. The majority of PPARα protein interactions have 
been identified using immunoprecipitation or yeast two hybrid approaches. Here we 
employed transfection of the human liver cell line HepG2 with a PPARα-YFP protein to 
identify the protein complex associated with PPARα. PPARα protein complexes were 
isolated by immunoprecipitation and interacting proteins were identified using mass 
spectrometry. We identified several unknown proteins involved in PPARα complex 
formation. One of the identified proteins, β-catenin, was previously described as 
a coregulator for PPARγ mediated gene activation. Other identified proteins were 
previously reported to play roles in the regulation of other transcription factors. The 
identified proteins may have an important function in transcriptional regulation by 
PPARα. 
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Introduction 
Diseases associated with disturbed energy homeostasis are an increasing problem 
in the western world (122,123). Amongst the genes involved in regulation of lipid 
metabolism, members of the Peroxisome Proliferator-Activated Receptors (PPARs) 
family predominate. PPARs, are part of the class II nuclear receptors (Mangelsdorf), 
that belong to the larger superfamily of nuclear receptors (10). Three PPAR subtypes 
have been identified so far, named PPARα (NR1C1), PPARβ/σ (NR1C2) and PPARγ 
(NR1C3) (124,125). All 3 receptors bind lipids or lipid derivates as the activating 
ligand (60). Binding of these ligands to PPARs will result in a conformational change 
in their ligand binding domain (LBD) (126), release of corepressors and recruitment of 
coactivators and components of the transcription machinery. These events ultimately 
lead to induction of PPAR target gene  expression. The majority of the PPAR target 
genes fare involved in lipid metabolism and lipid storage, but also genes involved in 
differentiation, proliferation and apoptosis are represented, depending on the type of 
tissue and the PPAR subtype investigated (10). In addition, PPARs are  therapeutic 
targets in many diseases involved in the disruption of normal metabolic pathways, 
such as obesity, atherosclerosis and type 2 diabetes, (127). To achieve transcription 
of PPAR target genes, PPAR forms an obligate heterodimer with the nuclear Retinoid 
X Receptor (RXR) (81). The DNA binding domains (DBD) of both PPAR and RXR are 
able to bind specific cis-acting PPAR responsive elements (PPREs) in the promoter 
region of PPAR target genes (125,128) PPREs are DR1 type responsive elements, 
which are structured by two repeated core AGGTCA consensus sequences with one 
nucleotide in between. The DBD of PPAR is positioned at the 5‘ prime side of PPREs 
and the DBD of RXR at the ‘3 prime  side (82). To investigate PPAR binding to DNA, 
several groups have used chromatin immunoprecipitation (ChIP) (129,130).  Upon 
ligand binding, high molecular mass coactivator complexes are formed with the PPAR/
RXR heterodimer (131). These highly dynamic complexes have multiple roles such 
as acetyltransferase activity, methyltransferase activity, ATP-dependant chromatin 
remodeling activity and they function as a mediator between the PPAR complex 
and the basal transcription machinery (103). Isolation of high molecular mass PPAR 
protein complexes in combination with identification by mass spectrometry was used 
to search for PPARα interacting proteins in rat liver tissue (132). 
We used a C terminal PPARα fusion with yellow fluorescence protein (YFP) for 
both ChIP and protein complex isolation experiments. Fusion proteins of PPARα 
with either YFP or GFP have been used before in localization studies of PPAR with 
confocal microscopy (133) and interaction studies of PPARs and RXR with Förster 
Resonance Energy Transfer (FRET) based techniques and Fluorescence Correlation 
28
Chapter 2
Spectroscopy (FCS) (131,134). 
In this work the human liver cell line HepG2 was used for both ChIP and protein 
complex isolation. After transient transfection with a PPARα-YFP expression construct, 
high molecular PPARα protein complexes were isolated by immunoprecipitation 
using GFP antibodies. Co-immunoprecipitated proteins were identified using  mass 
spectrometry.
Materials and Methods
Cell culture and transfection
HepG2 cells were grown in Dulbecco’s modified medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), penicillin, streptomycin and Amphotericin B. Cells 
were seeded at 30% confluence the day before the transfection. The next day cells 
were transfected with PPAR-pEYFP-n1 (CLONETECH) using the polyethylenimine 
method (135). In short, per 150 cm2, 30 μg expression vector was added to 790 μl 
150 mM NaCl. In parallel 237 μl 100mM polyethylenimine was added to 790 μl 150 
mM NaCl. After 15 minutes, both solutions were combined while vortexing and kept 
at room temperature for 30 minutes. To this solution culture medium lacking FBS 
was added  to 5 ml and mixed. The 150 cm2 plate was washed with PBS and 10 ml of 
culture medium without FBS was added. To this 10 ml the 5 ml mixture containing the 
expression vector was added and the flasks were incubated at 37 °C and 5% CO 2 for 
3 to 4 hours. Thereafter FBS was added to a final percentage of 10%.
Transactivation assay
HepG2 cells were grown in 6 well plates and cotransfected with PPAR-pEYFP-n1, 
PPRE-tk-LUC (Promega), control empty pcDNA vector (Invitrogen) and 
β-galactosidase. β-galactosidase activity was used to normalize for differences in 
transfection efficiencies. Transfected cells where treated with 50 mM Wy 14,643 or 
the solvent dimethylsulfoxide (DMSO) only. After 24 hours before luciferase activity 
was measured with a Promega luciferase assay kit (Promega) on a Fluoroskan 
Ascent Fl apparatus (Thermo labsystems). β-Galactosidase activity was measured 
in the cell lysate by a standard assay using 2-nitrophenyl-βD-galactopyranoside as 
a substrate.
RNA isolation and Quantitative PCR
Cells were scraped in TRIzol reagent (invitrogen) and RNA was extracted. 1 μg of 
RNA was used to reverse transcribe isolated RNA to cDNA with the iScript cDNA 
Synthesis Kit  (BioRad). Produced cDNA was used for qPCR measured on an iCycler 
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(BioRad) using platinum Taq polymerase (Invitrogen) and the double stranded 
DNA dye SYBR green. The following primers where used: Adipose differentiation 
related protein (ADFP), sense: 5’-TGAGATGGCAGAGAACGGTGTG-3’ and 
antisense: 5’-GGCATTGGCAACAATCTGAGT-3’. Carnitine palmitoyltransferase 
1A (CPT1A):  sense: 5’-CCCATTCGTAGCCTTTGGTA-3’ and antisense: 
5’-GCCTCGTATGTGAGGCAAAA-3’. 
Chromatin immunoprecipitation
ChIP experiments were performed based on the Degenhardt et al protocol (129). 
HepG2 cells were grown in 150 cm2 plates and transfected with PPAR-pEYFP-n1 
following the PEI transfection method (135). Cells were treated for 2 hours with 
either DMSO or PPARα ligand WY14,643.  To crosslink proteins to DNA, 37% 
formaldehyde was added to the medium to a final concentration of 1% and incubated 
for 15 minutes at room temperature. To stop crosslinking 1M glycine was added 
to a final concentration of 125 mM for 5 minutes. Cells were washed twice with 
PBS and scraped off the plastic, collected in PBS and centrifuged at 300g. The cell 
pellet was dissolved in lysis buffer (1% SDS, 10 mM EDTA, 50mM Tris-HCl, pH 8,0) 
and aliquots to a maximum of 300 μl were used for sonication as recommended by 
Diagnode. Aliquots where sonicated 8 times for 20 seconds, each sonication was 
followed by 40 seconds cooling on ice using the Bioruptor (Diagnode) at high power. 
Sonicated solution was centrifuged at maximum speed and the chromatin containing 
supernatants transferred. The supernatant was diluted 10 times with dilution buffer 
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM NaCl, 16.7 mM Tris-HCl, 
pH 8.0). 2 ml diluted chromatin was precleared for 1 hour with 40 μl of 50% v/v protein 
A/agarose beads  together with 10 μl of 0.1 μg/ul salmon sperm DNA.  Precleared 
chromatin was incubated overnight with 5 μg anti-YFP or without antibody as a 
control. Immunocomplexes were collected with 40 μl of proteinA/agarose beads and 
washed twice with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
150 mM NaCl, 20 mM Tris-HCl, pH 8.0), twice with  high salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0), twice 
with LiCl wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 
mM EDTA, 10 mM Tris-HCl, pH 8.0) and twice with TE buffer (1 mM EDTA, 10 mM 
Tris-HCl, pH 8.0). Immunoprecipitated chromatin was eluted off the beads with 250 
μl elution buffer (1% SDS 0.1 M NaHCO3) for 15 minutes. Supernatant was collected 
and the elution was repeated. The two eluates were combined and chromatin was 
decrosslinked at 65 °C overnight after addition of NaCl at a final concentration of 
200mM. Proteins were subsequently digested by incubation with 40 μg/ml proteinase 
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K for 1 hour at 45 °C. DNA fragments were purified by phenol/chloroform extraction, 
followed by ethanol precipitation. For PPRE analysis immunoprecipitated DNA was 
used for PCR with specific primers for each gene: CPT1APPRE sense: 
5’-AACTCGCTCCGGAAGGTCTC-3’, CPT1APPRE antisense: 
5’-GCTTGGAAAGCGTCCTCGGAAGG-3’ (136), IGFBP1PPRE 
sense: 5’-GATCCACCGTTATAGCCTCTG-3’ and IGFBP1PPRE 
antisense: 5’-CACCATCTTTGCCTCCCATTC-3’ (129), ADFP-PPRE 
sense: 5’-GCAAAAAGAAGCTTGCTCAG-3’, ADFP-PPRE antisense: 
5’-TGTTGCCATCTTCAGTGTTT-3’ (137). 
Immunoprecipitation
After treatments with WY14,643, HepG2 cells were washed with PBS and scraped 
in 10 ml PBS and pelleted at 300g. The pellet was resuspended in 2 ml of ice-cold 
hypotonic buffer (20 mM Hepes/NAOH, pH 7.5, 5 mM NaCl, 10 μM Na2MoO4, 0.1 
mM EDTA) and allowed to swell on ice for 15 minutes. The supernatant (cytoplasmic 
fraction) was removed and 1 ml was saved for western blot analysis. The pellet was 
re-suspended in 100 μl Nuclear Lysis Buffer (20 mM Hepes/NAOH, pH 7.5, 20% 
glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5% NP40) and mixed for 30 
minutes at 4°C . The extract was centrifuged with 13,200g  at 4° C to remove the 
insoluble fraction. The nuclear extract was diluted to a final concentration of 200 
mM KCl . Diluted nuclear extract was pre-cleared twice for 30 minutes with agarose 
beads (Pierce, Rockford, IL, USA) followed by 4 hours of incubation with agarose 
beads covalently coupled with αYFP at 4°C. Beads were washed twice with wash 
buffer (20 mM Hepes/NAOH pH 7.5, 20% glycerol, 150 mM KCl, 1.5 mM MgCl2, 0.2 
mM EDTA, 0.5% NP40) and twice with a 50 mM solution ammonium bicarbonate 
pH 8. 
Western Blot
Western blot analysis was performed using standard protocols. Proteins were 
separated on an 8% SDS-polyacrylamide gel and transferred to a polyvinylidene 
difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). αYFP (custom made) 
was used as primary antibody followed by 1 hour incubation with goat-α-rabbit 
IgG conjugated with horseradish peroxidase (Sigma). Bands were analyzed and 
quantified using the GelPro analysis software (Media Cybernetics Inc, Bethesda, 
MD, USA).
Sample preparation for mass spectrometry
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Immunoprecipitated samples were separated on an 8% SDS-PAGE gel. Subsequently 
the gel was stained with Coomassie blue (Colloidal blue Staining kit; Invitrogen, 
Paisley, UK). Strong visible bands were excised and remaining gel fragments from 
the lane were cut into equal fragments. Excised fragments were then cut into pieces 
of approximately 1 cm2. Gel pieces were washed twice with water and twice with 
50% AcNi/ammonium bicarbonate solution (pH 8) to remove coomassie from the 
gel. Gel pieces were incubated for 2 hours at 60° C with 50 mM dithiotreitol in 50 mM 
ammonium bicarbonate to reduce cysteine bonds.. After removal of DTT, proteins 
were alkylated by incubating the gel pieces with 100 mM iodoacetamide in 50 mM 
ammonium bicarbonate for at least 1 hour at room temperature and in the dark. 
Alkylation was stopped by 3 washes of 15 minutes with ammonium bicarbonate 
followed by a freeze thaw step to increase  accessible area. 50 ng/μl trypsin was 
added and incubated over night at room temperature. The next day the supernatant 
was collected in a clean low binding tube (Eppendorf GmbH, Germany). To the 
remaining gel pieces a 5% (v/v) TFA solution was added and sonicated for 1 minute. 
Subsequently, the TFA solution was removed and collected in the same low binding 
tube as the first supernatant. The procedure was repeated with a solution of 15% 
(v/v) acetonitril and 1% (v/v) TFA solution. All samples were stored at -80° C until 
LC-MS/MS analysis.
Mass spectrometry and data analysis
The prepared samples we analyzed with a capillary HPLC coupled to an ESI-ion-
trap mass spectrometer (LCQ, Finnigan matt GmbH, Bremen, Germany). The HPLC 
columns consisted of a protonsil 3 μm C18 pre-concentration column and analytical 
column (prepared in-house). A gradient of 10-72% acetonitril in 1% formic acid was 
used for elution of the peptides. Generated spectra were analyzed using the bioworks 
3.2 software (Bioworks, Fairport, NY, US). Threshold criteria were set according to 
peng et al. (138) to minimize false positives (less than 1%) in the analysis. Using 
these criteria all MS/MS spectra were compared against a humane protein database 
(European Bioinformatics Institute, database downloaded on February 2007) using 
the following criteria: enzyme: trypsin, DeltaCN: 0.08, Xcorr versus charge state: 
2.00; 1.50; 3.30, number of different peptides that must be found is 2, and a minimum 
protein probability of 0.01. 
Results
Characterization of the hPPARα-YFP fusion protein
To investigate the functionality of the hPPARα-YFP fusion protein, a transactivation 
32
Chapter 2
reporter assay was performed in HepG2 cells. Expression vectors were transfected 
with either wildtype PPARα, PPARα-YFP or as a control an empty expression vector. 
To measure the capability of the introduced proteins to activate a reporter gene 
via a PPAR responsive element, a construct was cotransfected that contains three 
repetitive PPREs, coupled to the luciferase reporter gene. As shown in figure 1A, 
endogenous PPARα in the control cells, cells transfected with PPARα-YFP and 
untagged wildtype PPARα all show an increased luciferase activity after addition of 
the synthetic PPARα agonist WY14,643. Luciferase activity induced by WY14,643 
treatment is increased with a similar relative degree of induction in control cells 
as well as in  PPARα-YFP and wildtype PPARα introduced cells. This suggests a 
normal activation role of the introduced PPARα-YFP protein. Increased basal and 
induced luciferase activity of  both PPARα-YFP and wildtype PPARα transfected 
cells are likely caused increased levels of PPARα proteins compared to endogenous 
PPARα present in the control cells. Although cells with introduced wildtype PPARα 
protein showed a higher luciferase activity when compared to PPARα-YFP, since 
the relative induction of luciferase is not affected. Increased luciferase activity is 
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Figure 1: Functional characterization of  PPARα-YFP. (A) PPARα-YFP shows normal transactivation 
capacity. HepG2 cells were transfected with PPARα-YFP, wildtype PPARα or control expression 
vectors. Luciferase activity was measured 24h after cells were treated with Wy14,643 or Vehicle 
(DMSO). β-galactosidase activity was measured to correct for differences in transfection efficiencies. 
(B)Transcriptional response of PPARα target genes ADFP and CPT1A induced by agonist Wy 14,643 
in HepG2 cells. Cells were incubated for  5 hours with PPARα agonist Wy 14,643. Expression levels 
of ADFP and CPT1A were measured in untransfected HepG2 cells as well as in PPARα wildtype, and 
PPARα-YFP transfected HepG2 cells. 
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likely due to a more efficient transcription/translation of wildtype PPARα compared 
to the larger fusion protein. The measured reporter gene induction by introduced 
human PPARα-YFP proteins are comparable with the findings for introduced murine 
PPARα-YFP in COS-1 cells in a comparable transactivation experiment (131). These 
results indicate that a fusion of YFP to PPARα does not alter the normal PPARα 
transactivation mechanism. 
Next it was determined whether introduction of PPARα-YFP fusion protein changes 
the transcription induction mechanism of PPARα target genes in HepG2 cells. 
Transcription levels of two known PPARα target genes in HepG2 cells, ADFP and 
CPT1α, were measured before and after 5 hours addition of WY14,643 or control 
vehicle DMSO. The results in figure 1B show that WY14,643 induced gene expression 
of  PPARα target genes CPT1α and ADFP did not change by the introduction of 
either PPARα-YFP or wildtype PPARα. This indicated that HepG2 cells contain a 
functional mechanism for PPAR target gene induction for CPT1α and ADFP that is 
not altered by the introduction of either extra wildtype PPARα or PPARα-YFP. 
DNA binding of PPARα-YFP to hPPARα target gene PPREs
To investigate if the introduced PPARα-YFP is taking part in the DNA binding protein 
complex responsible for transcriptional activation, Chromatin ImmunoPrecipitation 
(ChIP) experiments were performed. This technique was used to determine if 
PPARα-YFP is able to bind PPREs of the known PPARα target genes CPT1α, 
IGFBP1 and ADFP. PPARα-YFP was  introduced in HepG2 cells and stimulated 
with PPARα agonist WY14,64. Chromatin associated with PPARα-YFP was isolated 
by immunoprecipitation  with an antibody against the YFP tag. The precipitated 
ADRP
CPT1A
IGFBP1
Input control αYFP Input control αYFP
Control cells PPARα-YFP transfected cells
Figure 2: PPARα-YFP is involved in PPRE binding of PPARα target genes CPT1, IGFBP1 and ADFP. 
PPARα-YFP associated Chromatin was isolated by means of chromatin immunoprecipitation with the use 
of YFP specific antibodies. Purified chromatin was analyzed by PCR for the presence of known PPREs 
for CPT1α, IGFBP1 and ADFP by PCR.
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chromatin was analyzed for interactions of PPARα-YFP with known PPREs of three 
PPARα target genes CPT1α, IGFBP1 and ADFP. As shown in figure 2, PPREs of 
the three known PPARα target genes could be isolated and amplified. These results 
show the involvement of PPARα-YFP in DNA binding protein complexes responsible 
for the transcriptional activation of PPARα target genes. Furthermore we show that 
tagged PPARα can be used for isolating and analyzing PPARα target gene response 
elements with ChIP. 
PPARα-YFP complex analysis 
To isolate PPARα associated proteins, immunoprecipitation on protein extracts 
isolated from HepG2 cells was performed.  Western blotting was employed to confirm 
whether PPARα-YFP was present in isolated protein extracts from PPARα-YFP 
transfected HepG2 cells as well as for the verification of immunoprecipitations of 
PPARα-YFP. As shown in figure 3A, western blot analysis confirmed the presence of 
PPARα-YFP in protein extracts at its expected molecular weight of 80 kD as well as 
successful immunoprecipitation of PPARα-YFP with a YFP antibody. Quantification 
by measuring band intensities in relation to total protein of immunoprecipitatated 
PPARα-YFP suggested an approximate 30% recovery of PPARα-YFP from the 
protein extract.
To identify co-immunoprecipitated PPARα-interacting proteins, the immuno-
precipitated proteins were separated on a SDS-PAGE gel. Coomassie stained 
protein bands shown in figure 3B correspond to all proteins precipitated together 
with PPARα-YFP. For identification of the proteins co-precipitated with PPARα-YFP, 
predominant bands where cut out, followed by in-gel digestion and identification by 
LCQ mass-spectrometry. The remaining gel parts of the lanes were cut into smaller 
pieces and similarly analyzed. Using this approach PPARα and GFP where both 
identified (Figure 3B) in the band shown at 80kD. This molecular mass is in line with 
the expected size for the PPARα-YFP fusion protein. PPARα peptides were identified 
by means of mass spectrometry that represented  a  coverage of 30% of the whole 
PPARα protein (Figure 3C). A similar purification and identification procedure was 
executed to identify unspecific binding proteins by using control beads that did not 
have linked α-YFP. In table 1 all proteins co-purified with PPARα-YFP that were not 
present in the control purifications are listed.
The identified proteins were grouped according to their biological function. The 
largest group contains many proteins that are part of the (general) transcription 
machinery and RNA-processing mechanism. The majority of these proteins is part 
of a splicosome, has helicase activity or is involved in transcriptional initiation. 
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Several proteins identified were grouped by their involvement in the regulation of 
transcription. Obviously, the tagged protein, PPARα, is part of this group as well as 
a number of other proteins that are involved in transcriptional regulation. CTNNB1, 
DDX17, CAPER, RBAP48, SAP130, SNIP1, ku70 and LAP2 (TMPO) were all 
identified together with PPARα and have been previously identified to play a role 
in transcriptional regulation. The identified proteins, SF3B3 (SAP130), which is 
part of the coactivator complex STAGA, as well as, LAP2 (TMPO) that interacts 
with the deacetylation complex component HDAC3, were not found in control 
purifications, however they were previously marked as proteins unspecifically 
binding in immunoprecipitations and therefore might be unspecific binders in our 
experiments as well (139). Among the remaining proteins within the transcriptional 
regulation group, β-Catenin (CTNNB1) was previously reported to physically interact 
with PPARγ (140) as well as a function as coactivator when bound to the nuclear 
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Figure 3: Purification and identification of proteins associated with immuno-purified PPARα-YFP 
associated proteins. (A) transfected PPARα-YFP was detected by westernblot at its expected size of 
80kD in cellular fractions of PPARα-YFP introduced cells. As well as detection of immunoprecipitated 
PPARα-YFP with the use of an αYFP antibody. (B) SDS-PAGE analysis and coomassie staining of 
proteins non-specifically bound to agarose beats without αYFP coupled (lane1) as well as proteins 
immunoprecipitated together with PPARα-YFP (lane 2). (C) Identified peptides of  PPARα from the band 
at 80kD (in red). Total PPARα protein coverage was approximately 30%.
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Transcription and RNA processing
Refseq gene function
NP_054733 ASCC3L1 ACTIVATING SIGNAL COINTEGRATOR 1 
COM PLEX SUBUNIT 3-LIKE 1
RNA splicing
NP_542165 BAT1 HLA-B ASSOCIATED TRANSCRIPT 1 nuclear mRNA splicing, via spliceosome
NP_777573 C14ORF21 CHROM OSOM E 14 OPEN READING FRAM E 21 RNA binding
NP_006101 CD2BP2 CD2 ANTIGEN (CYTOPLASM IC TAIL) BINDING 
PROTEIN 2
nuclear mRNA splicing, via spliceosome
NP_037423 CPSF1 CLEAVAGE AND POLYADENYLATION SPECIFIC 
FACTOR 1, 160KDA
3-prime processing of pre-mRNAs
NP_006764 DDX18 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 18 ATP-dependent RNA helicase act ivity
NP_001347 DDX3X DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 3, 
X-LINKED
ATP-dependent RNA helicase act ivity
NP_057439 DDX47 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 47 ATP-dependent RNA helicase act ivity
NP_008941 DDX52 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 52 ATP-dependent RNA helicase act ivity
NP_065987 DDX55 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 55 ATP-dependent RNA helicase act ivity
NP_001354 DKC1 DYSKERATOSIS CONGENITA 1, DYSKERIN RNA processing
NP_004238 EFTUD2 ELONGATION FACTOR TU GTP BINDING DOM AIN 
CONTAINING 2
nuclear mRNA splicing, via spliceosome
NP_003744 EIF3D EUKARYOTIC TRANSLATION INITIATION FACTOR 
3, SUBUNIT 7 ZETA, 66/67KDA
regulat ion of translat ional init iat ion
NP_057175 EIF3EIP EUKARYOTIC TRANSLATION INITIATION FACTOR 
3, SUBUNIT 6 INTERACTING PROT...
regulat ion of translat ional init iat ion
NP_003745 EIF3F EUKARYOTIC TRANSLATION INITIATION FACTOR 
3, SUBUNIT 5 EPSILON, 47KDA
regulat ion of translat ional init iat ion
NP_003751 EIF4G3 EUKARYOTIC TRANSLATION INITIATION FACTOR 
4 GAM M A, 3
regulat ion of translat ional init iat ion
NP_002676 EXOSC10 EXOSOM E COM PONENT 10 RNA processing
NP_060117 FTSJ3 HYPOTHETICAL PROTEIN FLJ20062 rRNA methylat ion
NP_036473 GTPBP4 GTP BINDING PROTEIN 4 negative regulat ion of DNA replicat ion
NP_001005335 HNRNPL HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN L
nuclear mRNA splicing, via spliceosome
NP_005817 HNRNPR HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN R
nuclear mRNA splicing, via spliceosome
NP_001027565 HNRPH2 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN H2 (H')
nuclear mRNA splicing, via spliceosome
NP_112480 HNRPM  HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN M
nuclear mRNA splicing, via spliceosome
NP_006537 IGF2BP1 INSULIN-LIKE GROWTH FACTOR 2 M RNA 
BINDING PROTEIN 1
binding to the 5' UTR of the insulin-like growth factor 2 (IGF2) mRNA and 
regulat ing IGF2 translat ion
NP_006538 IGF2BP3 
INSULIN-LIKE GROWTH FACTOR 2 M RNA 
BINDING PROTEIN 3
bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may 
repress translat ion of insulin-like growth factor II during late development
NP_076983 NOC4L NUCLEOLAR COM PLEX ASSOCIATED 4 
HOM OLOG (S. CEREVISIAE)
small nucleolar ribonucleoprotein complex
NP_001028886 NOL1 NUCLEOLAR PROTEIN 1, 120KDA small nucleolar ribonucleoprotein complex
NP_079170 NOL10 NUCLEOLAR PROTEIN 10 small nucleolar ribonucleoprotein complex
NP_631981 NOL6 NUCLEOLAR PROTEIN FAM ILY 6 (RNA-
ASSOCIATED)
small nucleolar ribonucleoprotein complex
NP_002517  NT5E    5'-NUCLEOTIDASE, ECTO (CD73) DNA metabolic process
NP_002559 PABPC1 POLY(A) BINDING PROTEIN, CYTOPLASM IC 2 poly(A) shortening and translat ion init iat ion
NP_115687 POLDIP3 POLYM ERASE (DNA-DIRECTED), DELTA 
INTERACTING PROTEIN 3
interacts with the DNA polymerase delta p50 subunit , specif ic target of S6 
kinase 1 and regulates cell growth
NP_006436 PRPF8 PRP8 PRE-M RNA PROCESSING FACTOR 8 
HOM OLOG (YEAST)
essential for the catalyt ic step II in pre-mRNA splicing process
NP_002904 RFC1 
REPLICATION FACTOR C (ACTIVATOR 1) 1, 
145KDA
activator of DNA polymerases, binds to the 3' end of primers, and promotes 
coordinated synthesis of both strands. It  also may have a role in telomere 
stability
NP_056474 RSL1D1 RIBOSOM AL L1 DOM AIN CONTAINING 1 RNA processing
NP_003698 RUVBL1 RUVB-LIKE 1 (E. COLI) DNA helicase act ivity, chromatin modif icat ion
NP_006657 RUVBL2 RUVB-LIKE 2 (E. COLI) DNA helicase act ivity, chromatin modif icat ion
NP_056455 SERBP1 SERPINE1 M RNA BINDING PROTEIN 1 regulat ion of mRNA stability
NP_006793 SF3A3 SPLICING FACTOR 3A, SUBUNIT 3, 60KDA
The splicing factor 3a heterotrimer includes subunits 1, 2 and 3 and is 
necessary for the in vitro conversion of 15S U2 snRNP into an act ive 17S 
part icle that performs pre-mRNA splicing
NP_005841 SF3B4 SPLICING FACTOR 3B, SUBUNIT 4, 49KDA
The splicing factor 3a heterotrimer includes subunits 1, 2 and 3 and is 
necessary for the in vitro conversion of 15S U2 snRNP into an act ive 17S 
part icle that performs pre-mRNA splicing
NP_775105 SHPRH SNF2 HISTONE LINKER PHD RING HELICASE contains motifs characterist ics of several DNA repair proteins, transcript ion 
factors, and helicases
NP_055045 SRP68 SIGNAL RECOGNITION PARTICLE 68KDA ribonucleoprotein complex that transports secreted and membrane proteins 
to the endoplasmic ret iculum for processing
NP_009123 SUPT16H SUPPRESSOR OF TY 16 HOM OLOG (S. 
CEREVISIAE)
posit ive transcript ion elongation factor act ivity
NP_006363 SYNCRIP SYNAPTOTAGM IN BINDING, CYTOPLASM IC RNA 
INTERACTING PROTEIN
RNA splicing
NP_057085 UTP18 WD REPEAT DOM AIN 50 rRNA processing
NP_065101 UTP3 DISRUPTER OF SILENCING 10
Table 1: PPARα-YFP interacting proteins identified with mass-spectrometry. Proteins 
Immunoprecipitated together with PPARα-YFP were identified using mass-spectrometry. Proteins 
identified in control samples were subtracted and remaining proteins classified according to their known 
biological function.
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Transcriptional regulation
Refseq gene function
NP_001895 CTNNB1 CATENIN (CADHERIN-ASSOCIATED PROTEIN), 
BETA 1, 88KDA
many roles; transcript ion coact ivator act ivity; bind rxra
NP_006377 DDX17 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 17
p72 is an important transcript ional regulator, funct ioning as a co-act ivator 
and/or co-repressor depending on the context of the promoter & the 
transcript ional complex
NP_849181 HNF4A HEPATOCYTE NUCLEAR FACTOR 4, ALPHA nuclear receptor, fatty acid binding
NP_001001929 PPARA PEROXISOM E PROLIFERATIVE ACTIVATED 
RECEPTOR, ALPHA
nuclear receptor
NP_005601 RBBP4 RETINOBLASTOM A BINDING PROTEIN 4
It  is part of the M i-2 complex which has been implicated in chromatin 
remodeling and transcript ional repression associated with histone 
deacetylat ion. This encoded protein is also part of  co-repressor complexes, 
which is an integral component of transcript ional silencing
NP_909132 RBM 39 RNA-BINDING REGION (RNP1, RRM ) CONTAINING 
2
this protein may act as a transcript ional coact ivator for JUN/AP-1 and 
estrogen receptors
NP_036558 SF3B3 KIAA0017 GENE PRODUCT
Subunit  3 has also been identif ied as a component of the STAGA (SPT3-
TAF(II)31-GCN5L acetylase) transcript ion coact ivator-HAT (histone 
acetyltransferase) complex, and the TFTC (TATA-binding-protein-free 
TAF(II)-containing complex). These complexes may funct ion in chromatin 
modif icat ion, transcript ion, splicing, and DNA repair
NP_078976 SNIP1 SM AD NUCLEAR INTERACTING PROTEIN 1 regulat ion of transcript ion, DNA-dependent
NP_001027454 TM PO THYM OPOIETIN regulat ion of transcript ion
NP_001460 XRCC6 X-RAY REPAIR COM PLEM ENTING DEFECTIVE 
REPAIR IN CHINESE HAM STER CELLS 6.
Ku70, posit ive regulat ion of transcript ion, DNA-dependent, DNA ligat ion
NP_036388 ZNF212 ZINC FINGER PROTEIN 212 regulat ion of transcript ion, DNA-dependent
NP_060651 ZNF532 ZINC FINGER PROTEIN 532 regulat ion of transcript ion, DNA-dependent
Cell cycle
Refseq gene funct ion
NP_009117 CEP250 CENTROSOM AL PROTEIN 250KDA mitot ic cell cycle
NP_006550 KHDRBS1 KH DOM AIN CONTAINING, RNA BINDING, SIGNAL 
TRANSDUCTION ASSOCIATED 1
G2/M  transit ion of mitot ic cell cycle
NP_003972 PRC1 PROTEIN REGULATOR OF CYTOKINESIS 1 mitot ic spindle elongation, cytokinesis
NP_065726 SPC25 SPINDLE POLE BODY COM PONENT 25 HOM OLOG 
(S. CEREVISIAE)
involved in kinetochore-microtubule interact ion and spindle checkpoint 
act ivity
NP_004475 GPC3 GLYPICAN 3 control of cell division and growth regulat ion
NP_056145 SPECC1L KIAA0376 PROTEIN cell cycle
Metabolic process
Refseq gene function
NP_002849 ABCD3 ATP-BINDING CASSETTE, SUB-FAM ILY D (ALD), 
M EM BER 3
peroxisomal import of fatty acids and/or fatty acyl-CoAs
P_079523  ACAD10    ACYL-COENZYM E A DEHYDROGENASE FAM ILY, 
M EM BER 10
beta-oxidat ion of fatty acids in mitochondria
NP_004448 ACSL3 ACYL-COA SYNTHETASE LONG-CHAIN FAM ILY 
M EM BER 3
fatty acid metabolic process
NP_001924 DLST DIHYDROLIPOAM IDE S-SUCCINYLTRANSFERASE 
(E2 COM PONENT OF 2-OXO-GLUTARAT...
acyltransferase act ivity, metabolic process
NP_078782 GLB1L GALACTOSIDASE, BETA 1-LIKE carbohydrate metabolic process
NP_991404 LSR LIPOLYSIS STIM ULATED LIPOPROTEIN RECEPTOR liver development, in LDL, VLDL and chylomicron
NP_078938 NAT10 N-ACETYLTRANSFERASE 10 N-acetyltransferase act ivity, metabolic process
Protein degration
Refseq gene funct ion
NP_001141 ANPEP ALANYL (M EM BRANE) AM INOPEPTIDASE 
(AM INOPEPTIDASE N, AM INOPEPTIDASE M , …
final digest ion of peptides generated from hydrolysis of proteins by gastric 
and pancreatic proteases
NP_004404 DPEP1 DIPEPTIDASE 1 (RENAL) dipeptidase act ivity; proteolysis
NP_005349 LM O7 LIM  DOM AIN 7 ubiquit in-protein ligase act ivity
NP_872607 UBE2E1 UBIQUITIN-CONJUGATING ENZYM E E2E 1 
(UBC4/5 HOM OLOG, YEAST)
E2 ubiquit in-conjugating enzyme
NP_003461 USP7 UBIQUITIN SPECIFIC PEPTIDASE 7 (HERPES VIRUS-
ASSOCIATED)
ubiquit in-dependent protein catabolic process
Structural proteins
Refseq gene funct ion
NP_005222 CTTN CORTACTIN myosin and act in binding
NP_004386 DBN1 DREBRIN 1 act in binding
NP_002009 FLII FLIGHTLESS I HOM OLOG (DROSOPHILA) act in binding
NP_004466 FLOT2 FLOTILLIN 2 cell adhesion
NP_443137 FM NL2 FORM IN-LIKE 2 act in binding
NP_783863 FM NL3 FORM IN-LIKE 3 act in binding
NP_068831 JUP JUNCTION PLAKOGLOBIN cytoskeletal protein binding
NP_002254 KIFC1 KINESIN FAM ILY M EM BER C1 microtubule motor act ivity
NP_005549 LAD1 LADININ 1 structural molecule act ivity
NP_055949 M -RIP M YOSIN PHOSPHATASE-RHO INTERACTING 
PROTEIN
actin binding
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androgen receptor (141). The helicase DDX17 (p72) has been reported to act as 
a coregulator of estrogen receptor transactivation by bridging the receptor to the 
SRA/SRC1 coactivator complex (142). RBM39 (CAPER) was found to have a dual 
function: coactivation of the progresterone receptor and estrogen receptor as well as 
a function in pre-RNA splicing (143). RBB4 (RBAP48) is part of histone deacetylation 
and chromatin remodeling complexes (144). SNIP1 binds to the p300/CBP complex 
resulting in repression of transactivation of SMAD and RelA(p65) nuclear factor-κB 
subunit. In contrast, SNIP1 recruits the p300/CBP complex to c-Myc and thereby 
increasing its activity. XRCC6 (ku70) is mainly involved in DNA repair, but it has 
also been reported to negatively regulate the activity if the ESE-1 transcription 
factor by binding to its DNA binding domain (145). About two other proteins in the 
transcriptional regulation group, ZNF212 and ZNF532, not much is known, besides 
the presence of a DNA binding zinc-finger motif. 
Proteins identified and grouped according to their main function in cell structure 
contained mainly proteins that bind either actin or myosin. Since actin and myosin 
are the strongest unspecific binders in our experiments, some co-purification of non 
specific actin and myosin binding proteins would be expected. Several proteins that are 
NP_002471 PPP1R12A PROTEIN PHOSPHATASE 1, REGULATORY 
(INHIBITOR) SUBUNIT 12A
myosin-binding subunit  of myosin phosphatase
NP_066301 SNTB1 SYNTROPHIN, BETA 1 (DYSTROPHIN-
ASSOCIATED PROTEIN A1, 59KDA, BASIC COM ...
act in binding, associated with dystrophin and dystrophin-related proteins
NP_003119 SPTBN1 SPECTRIN, BETA, NON-ERYTHROCYTIC 1 act in crosslinking and molecular scaffold protein that links the plasma 
membrane to the act in cytoskeleton
NP_055362 TM OD3 TROPOM ODULIN 3 (UBIQUITOUS) act in binding
NP_061978 TNXB TENASCIN XB actin cytoskeleton organizat ion
Others
Refseq gene funct ion
NP_671492 AKAP2 A KINASE (PRKA) ANCHOR PROTEIN 2 enzyme binding
NP_877952 ARS2 ARS2 PROTEIN response to arsenic
NP_001681 ATP6V1A ATPASE, H+ TRANSPORTING, LYSOSOM AL 
70KDA, V1 SUBUNIT A
proton-transport ing ATPase act ivity, rotat ional mechanism
NP_060063 BM P2K BM P2 INDUCIBLE KINASE protein amino acid phosphorylat ion
NP_064583 CCDC47 COILED-COIL DOM AIN CONTAINING 47 lit t le known
NP_005207 DDOST DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE-
PROTEIN GLYCOSYLTRANSFERASE
protein amino acid N-linked glycosylat ion via asparagine
NP_001934 DSG2 DESM OGLEIN 2 calcium-binding transmembrane glycoprotein component of desmosomes in 
vertebrate epithelial cells
NP_085139 EEPD1 KIAA1706 PROTEIN sequence-specif ic DNA binding
NP_004422 EPHA2 EPH RECEPTOR A2 ephrin receptor signaling pathway
NP_000121 F5 
COAGULATION FACTOR V (PROACCELERIN, 
LABILE FACTOR) cofactor of the blood coagulat ion cascade
NP_690002 FAM 133B HYPOTHETICAL PROTEIN M GC40405 lit t le known
NP_002147 HSPD1 HEAT SHOCK 60KDA PROTEIN 1 (CHAPERONIN) folding and assembly of newly imported proteins in the mitochondria
NP_056350 LOC26010 DNA POLYM ERASE-TRANSACTIVATED PROTEIN 
6
lit t le known
NP_361013 LUZP1 LEUCINE ZIPPER PROTEIN 1 lit t le known
NP_057307 PACSIN3 PROTEIN KINASE C AND CASEIN KINASE 
SUBSTRATE IN NEURONS 3
negative regulat ion of endocytosis
XP_496907 PEG10 PATERNALLY EXPRESSED 10 apoptosis cell, dif ferent iat ion, proteolysis, transposit ion
XP_940277 PXDN PEROXIDASIN HOM OLOG (DROSOPHILA) hydrogen peroxide catabolic process, immune response, oxidoreductase 
act ivity
NP_056392 RAI14 RETINOIC ACID INDUCED 14 lit t le known
Structural proteins (continued)
Refseq gene funct ion
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predicted to have a function in the cell cycle, metabolic process, protein degradation 
as well as proteins that do not fall into a precise category were identified. These 
proteins have their main localization and/or function in compartments other then 
the nucleus. Therefore these co-precipitated proteins are not likely to be involved in 
transcriptional regulation and might be unspecific binders. However, it was reported 
that the mitochondrial enzyme 3-hydroxy-3-methylglutaryl-CoA synthase (mHMG-
CoAS) is able to bind to PPARα and translocate to the nucleus to enhance its own 
expression by inducing PPARα activity (146). Therefore the proteins that are part of 
the metabolic processes group ACSL3 and ABCD3, which are regulated by PPARα 
(14,147,148) as well as the genes involved in lipid metabolism LSR and ACAD10 
cannot be easily discarded since a similar mechanism as found for mHMG-CoAS 
may be involved.
In conclusion, various proteins identified are part of coregulatory complexes and may 
play a role in PPAR gene regulation. The proteins that were co-purified with PPARα-
YFP,  β-catenin, DDX17, CAPER, RBAP48, SNIP1, ku70, ZNF212 and ZNF532 
were not reported before to interact with PPARα. However, for β-catenin (CTNNB1) 
physical interaction was shown with the PPARγ isotype. DDX17, CAPER, SNIP1 
and RBAP48 all play a role in transcriptional activation or repression of other nuclear 
receptors that share many regulatory mechanisms with PPARs. Therefore these 
proteins may have a similar functional role in PPARα transcriptional activity. Previous 
identified PPARα interactors such as PGC1α, CBP and PBP (103) however were not 
detected using our approach. Furthermore, the results show that the methodology 
used is sensitive enough to individually identify PPARα-YFP, as well as identification 
of several interacting nuclear proteins involved in transcription. 
Discussion
Activation of a PPAR target gene is a complex and dynamic event, depending on 
many factors. The type of ligand, expression levels and posttranslational state of the 
different PPARs are involved as well as the coregulators and transcription factors 
interplaying with the receptor. Depending on the combination of all these factors, a 
coactivator complex forms and expression of a PPAR target genes is initiated (93). 
Differences in target gene activation and PPRE binding for the three PPAR subtypes 
is another factor involved in PPAR gene regulation. It is reported that PPRE selection 
by PPAR subtype is determined by the ‘5 prime flanking region of the PPRE (85). 
This is one factor explaining PPAR isotype discrimination between target gene 
inductions, but still have the same core PPRE motif. 
To study the composition of PPARα protein complexes, isolation and identification 
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of their subunits is very important. A PPARα-YFP fusion protein was constructed to 
apply a specific antibody against the YFP tag for immunoprecipitation of PPARα and 
associated proteins. Before using  PPARα-YFP for this purpose, an examination of 
functionality of the fusion protein was performed. The addition of functional PPARα 
in a gene reporter assay should result in an increase of transactivation by PPARα 
compared to only endogenous present PPARα in control cells. Both introduced 
wildtype PPARα as well as PPARα-YFP show this increase in transactivation in 
both basal as well as ligand induced cells. Only a slightly higher relative induction 
of the reporter gene by PPARα-YFP was found compared to introduced wildtype 
PPARα.  However, cells introduced with wildtype PPARα showed a higher basal and 
induced transactivation activity compared to PPARα-YFP introduced cells. These 
lower levels seen for PPARα-YFP might be caused by a less efficient transcription/
translation of the larger fusion protein. In contrast, when stimulating HepG2 cells 
with agonist, gene induction of the two well studied PPARα target genes CPT1A and 
ADFP were similarly upregulated in control cells as well as in wildtype PPARα and 
PPARα-YFP transfected cells. Basal and Induced levels of the target genes show 
no differences between the control cells and the transfected cells This indicates 
that overexpressed PPARα-YFP is not affecting expression mechanisms induced 
by PPARα in the genomic context of HepG2 cells. Possibly the limited availability 
of only two binding sites per gene per cell may cause no further enhancement of 
transcription of PPARα target genes by the addition of more PPARα protein.
To further investigate if PPARα-YFP is involved in activation of PPARα target genes 
in HepG2 cells, ChIP experiments were performed. ChIP showed that PPARα-YFP 
is able to bind PPAR responsive elements of three previously reported PPARα 
target genes ADFP, CPT1α and IGFBP1. The ability to bind to PPREs without 
impairing gene expression suggests that PPARα-YFP is functional in the genomic 
context of HepG2 cells. The expression data and PPRE binding data combined, 
shows that PPARα-YFP is able to bind PPREs of known PPAR target genes without 
affecting normal expression mechanisms, suggesting PPARα-YFP is indeed able to 
activate PPAR target gene expression. However the data does reveal the portion 
of gene activation that is contributed by PPARα-YFP and what part is achieved by 
endogenously present PPARα. 
An antibody against YFP was used to isolate proteins associated with ligand induced 
PPARα-YFP. We successfully isolated and identified both PPARα as well as the 
YFP tag from HepG2 protein extracts.  Several proteins were identified that were 
co-purified together with PPARα-YFP. These copurified proteins were grouped 
according to their, if available, known biological function. The largest group of proteins 
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that was identified contained proteins involved in transcription and RNA processing. 
Proteins in both these processes are involved in the transcriptional process of genes. 
The group of identified proteins that involves transcriptional regulation contains 
proteins that are either part of transcriptional activation or transcriptional repression. 
β-Catenin, DDX17, CAPER, RBAP48, SAP130, SNIP1, ku70 and LAP2 (TMPO) 
were previously identified as coregulators of other transcription factors. For two of 
them, SAP130 and LAP2, it was shown by others that they are frequently purified 
unspecifically in immunoprecipitations (139) and therefore likely unspecific in our 
experiments as well. Within the remaining proteins of this group, β-catenin was 
reported to interact with PPARγ. It was shown that induction of the wnt/β-catenin 
pathway was able to activate a PPARγ target gene, linking the PPARγ pathway 
to wnt/β-catenin signaling (140). A possible mechanism for PPARγ gene activation 
may be similar to the mechanisms found for the androgen receptor (149). Such 
a mechanism would recruit the p300/CBP complex to PPARγ mediated by the 
binding of β-catenin to PPARγ. Since β-catenin binding to PPARα was found in our 
immunoprecipitations, a similar mechanism may be involved in PPARα activation. 
Furthermore, DDX17 and CAPER have been reported previously to play a role in 
the activation of nuclear receptors other the PPARα. These proteins could very well 
be candidates to show similar regulatory functions in the regulation of PPARα target 
genes (141-143). SNIP1 was not yet linked to functions in the regulation of nuclear 
receptors, however, binding of this protein to the p300/CBP complex was reported. 
This coactivation complex is involved in the activation of many nuclear receptors, 
including the PPARs (150).  SNIP1 could possibly play a role in PPARα regulation 
via its interaction with the p300/CBP co-activation complex.
In addition, RBAP48, and ku70 are reported to function as co-repressors of some 
transcription factors. RBAP48 is involved in histone deacetylation, which represses 
the access for proteins to interact with DNA. This repressed accessibility may lead 
to reduction of transcriptional activity. Recently it was shown that this protein was 
involved in repression of ER target genes (144). Ku70 downregulates expression 
by direct binding to the DNA binding domain of the ESE-1 transcription factor. 
Interestingly, in a study performed by Jung et al. (139), two of the proteins identified, 
CAPER and ku70, were reported to interact with each other.  A protein complex 
containing these two proteins may have a role in transcriptional regulation of nuclear 
receptors. 
Besides the proteins involved in regulation of transcription and RNA processing, 
we found several groups involved in other biological processes that are not directly 
linked to transcription. Within the group “metabolic process”, several proteins 
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previously identified to be regulated by PPARs were found, such as ACSL3 and 
ABCD3  (14,147,148). However for these genes no known function in PPAR 
regulation has been reported. A mechanism as described for the mitochondrial 
enzyme 3-hydroxy-3-methylglutaryl-CoA synthase (mHMG-CoAS) could be a 
possible mechanism in the regulation of these genes.   mHMG-CoAS is able to bind 
directly to PPARα and potentiate PPARα transcriptional activity via its own PPRE 
(146). An LXXLL protein motif was found in mHMG-CoAS. This motif is a highly 
conserved amphiphatic α-helix that binds to the AF-2 region of nuclear receptors and 
is responsible for ligand dependant transcriptional activation (93). Possibly ACSL3, 
ABCD3 LSR and ACAD10 are able to regulate their own transcriptional activity in a 
manner similar to mHMG-CoAS. However experiments proving physical interactions 
between these metabolic enzymes and PPARα are required. 
Proteins classified among the remaining groups “cell cycle”, “protein degradation”, 
“structural proteins” and proteins that did not fall into any of the biological groups, do 
not contain any proteins previously identified as PPAR interacting. Since we used a 
rapidly dividing cancer derived cell line, these cells may contain elevated levels of 
proteins involved in the cell cycle. Because of these elevated levels, there might be a 
higher degree of non-specifically binding proteins purified within the cell cycle group. 
Furthermore proteins grouped in “structural proteins” mainly consist of proteins 
interacting with cytoskeleton proteins such as actin and myosin. These two proteins 
are the strongest non-specific binders in our experiments, therefore binders to actin 
and myosin are most likely non-specific as well. Furthermore, a number of identified 
proteins might be non-specifically purified from the protein extracts that may be 
the result of the methodological approach we used. In any proteomic experiment 
it is of critical importance to find the optimal balance between the reduction of non-
specifically binding of proteins by wash steps and still keep weak protein interactions 
intact. We used a one step immuno purification method, which may not be sufficient 
to lower the background noise, caused by non-specifically binding proteins, to a 
level that would make the identification of less abundant and weaker interacting 
proteins possible. To achieve a better signal to noise ratio for proteomic experiments 
in HepG2 cells, a specific two step purification designed for the use in mammalian 
cells might be an option that could improve enrichment of tagged proteins up to ten 
fold (151). Furthermore, recently a study using a one step purification approach to 
identify prostate derived Ets transcription factor (PDEF) interacting proteins identified 
over 200 interacting proteins. They used a statistical method that compared their 
data to published protein-protein interaction data to identify non-specific proteins 
with a high probability (152). This kind of algorithms might be a promising addition to 
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further minimize false positives among proteomic data.  
Most protein-protein interactions found for nuclear receptors were identified using 
a GST pull-down assay with in vitro produced labeled protein or a two hybrid 
approach. Not many studies have addressed protein-protein interaction using 
immunoprecipitation followed by mass-spectrometry in nuclear receptor research. 
One study used extracts from rat liver tissue instead of cell line derived extracts for 
the identification of PPARα interacting proteins. Several previously reported nuclear 
receptors interacting proteins were found, such as CBP, PGC1a  and SRC-1 (132). 
We did not identify these coactivators using extracts from HepG2 cells. Human cells 
respond less potent in response to PPAR activation compared to rat derived FAO cells 
(153). A less stable or different protein complex formed in human cells could explain 
the absence of these coactivators in the proteins identified in HepG2 cells and may 
account for the lower transcriptional inductions found in human. Furthermore, with 
the increased presence of PPARα in an overexpression situation, interactions with 
the proteins we identified might be enriched, possibly because of limited coactivators 
available.  Several studies have used a similar approach as in our experiments, using 
a one step immuno-purification or GST pull down assay with cell extracts followed by 
identification of purified proteins resolved by SDS-PAGE gel separation with mass 
spectrometry (154). Mayeur et. al. used this technique to identify proteins associated 
with the androgen receptor (AR) (155). They were able to show interaction of the non 
ligand activated AR with Ku70, which we also identified as interactor of PPARα, as 
well as Ku80 and the DNA-PK complex. Similar as shown in our results, they did not 
find back frequently described nuclear receptor coactivators. 
To conclude, our transactivation, quantitative PCR and ChIP experiments together 
showed no major disturbance in transcriptional activation of PPARα target genes 
and the ability to bind to PPREs was preserved. Several unknown proteins involved 
in PPARα complex formation were identified. However one of the identified 
proteins, β-catenin, was previously described as coactivator for PPARγ activation. 
The identified proteins may have an important function in PPARα transcriptional 
regulation and further research will be necessary to exactly determine the individual 
functions of these proteins. 
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Abstract
The transcription factor Peroxisome Proliferator-Activated Receptor α (PPARα) is an 
important regulator of hepatic lipid metabolism. While PPARα is known to activate 
transcription of numerous genes, no comprehensive picture of PPARα binding to 
endogenous genes has yet been reported. To fill this gap, we performed ChIP-chip 
in combination with transcriptional profiling on HepG2 human hepatoma cells treated 
with the PPARα agonist GW7647. We found that GW7647 increased PPARα binding 
to 4220 binding regions. GW7647-induced binding regions showed a bias around the 
transcription start site and most contained a predicted PPAR binding motif. Several 
genes known to be regulated by PPARα, such as ACOX1, SULT2A1, ACADL, CD36, 
IGFBP1 and G0S2, showed GW7647-induced PPARα binding to their promoter. 
A GW7647-induced PPARα-binding region was also assigned to SREBP-targets 
HMGCS1, HMGCR, FDFT1, SC4MOL, and LPIN1, expression of which was induced 
by GW7647, suggesting cross-talk between PPARα and SREBP signaling. Our data 
furthermore demonstrate interaction between PPARα and STAT transcription factors 
in PPARα-mediated transcriptional repression, and suggest interaction between 
PPARα and TBP and C/EBPα in PPARα-mediated transcriptional activation. Overall, 
our analysis leads to important new insights into the mechanisms and impact of 
transcriptional regulation by PPARα in human liver and highlight the importance of 
cross-talk with other transcription factors.
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Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors (TFs) that play an important role in the regulation of numerous 
biological processes, including lipid metabolism, adipocyte differentiation, cell 
proliferation and inflammation (10). Three different highly conserved PPAR isotypes 
have been identified: PPARα (NR1C1), PPARβ/σ (NR1C2) and PPARγ (NR1C3). The 
PPARα isotype has been shown to govern expression of numerous genes involved 
in fatty acid oxidation, ketogenesis, gluconeogenesis, cholesterol catabolism and 
lipoprotein metabolism (14,15). Additionally, PPARα has anti-inflammatory effects by 
suppressing pro-inflammatory genes (17,18). Consistent with its prominent function 
in lipid metabolism, PPARα is activated by various fatty acids and fatty acid derivates, 
as well as by synthetic agonists such as fenofibrate, WY14,643 and GW7647 (156). 
Analogous to several other nuclear receptors, PPARs form heterodimers with retinoid 
X receptors (RXRs) (81), which occurs independently of ligand or DNA binding (131). 
PPARs bind to DNA by recognizing specific cis-acting PPAR responsive elements 
(PPREs) present in the regulatory regions of PPAR target genes. The consensus 
PPRE consists of a direct repeat of the hexameric sequence AGGTCA separated by 
one less conserved spacer nucleotide. PPARα was shown to bind to the 5’ motif of the 
PPRE, whereas RXR binds to the 3’ motif (82). Full activation of gene transcription 
by the DNA-bound PPAR-RXR complex is ultimately dependent on the formation of 
a larger transcription initiation protein complex via recruitment of a number of co-
activator proteins and RNA polymerase II (88). Additionally, PPARα has been shown 
to downregulate gene expression by interfering with the activity of other transcription 
factors (157,158).
Recent studies using chromatin immunoprecipitation (ChIP) in combination with 
genomic tilling microarrays or sequencing (ChIP-chip or ChIP-Seq) have provided 
important new information on the requirements for DNA-binding by PPARs and 
other nuclear receptors. One of the most interesting findings was that genes that are 
activated by PPARγ show an enrichment of modules consisting of a PPRE-like motif 
together with a C/EBP binding element (84,86). It was found that knocking-down of 
either PPARγ or C/EBP reduced expression of several PPAR target genes, which 
was further reduced when these genes where knocked down simultaneously (86). 
A similar enrichment of a TF module was shown for the estrogen receptor (ER), 
which clustered together with forkhead, Oct1 and C/EBP motifs (89), as well as for 
the androgen receptor (AR) and the glucocorticoid receptor (GR) (90,91). These 
ChIP-chip studies thus reveal a complex interplay between nuclear receptors and 
other TFs. This cross-talk might be an important mechanism in gene regulation by 
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nuclear receptors and may be  responsible for transcriptional regulation of specific 
sets of genes.
While several studies have mapped the genomic binding regions of PPARγ, there are 
no reports available that describe the use of ChIP-chip or ChIP-Seq to investigate 
genomic binding of PPARα. Accordingly, in the present study we generated genome-
wide maps of PPARα binding regions in the HepG2 human hepatoma cell line using 
ChIP combined with human promoter tiling arrays. We used HepG2 cells because 
they represent the most widely used cellular model for human liver cells, despite 
the modest effects of PPARα activation on gene expression. Our analysis was 
targeted towards the discovery of promoter sites showing increased PPARα binding 
in response to PPARα activation by ligand. To investigate the relation between 
promoter occupancy by PPARα and regulation of gene expression, results of ChIP-
chip analysis were coupled to gene expression data. 
Materials and methods
Cell culture
HepG2 cells were grown in phenol red-free Dulbecco’s modified medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 0.1 mg/ml 
streptomycin and 100 U/ml penicillin. Cells were split the day before experiments. 
Cells were kept at 37 °C and 5% CO2. The following day cells were treated with 
either 100 nM of the PPARα agonist GW7647 or control vehicle (DMSO). Cells used 
for ChIP-chip analysis were harvested after 2 h of GW7647 treatment. Cells used for 
gene expression analysis were harvested after 6 h of GW7647 treatment.
ChIP
ChIP was performed as described previously (129). Briefly, protein-DNA complexes 
were cross-linked in 1% formaldehyde for 10 min at room temperature. Cross-linking 
was stopped by addition of 1 M glycine to a final concentration of 125 mM for 5 min. 
Cells were washed twice with PBS, scraped and collected by centrifugation. The 
cell pellet was dissolved in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 
8.0). Extracts were sonicated using the Bioruptor (Diagenode) at high power until 
DNA fragments of approximately 500-1000 bp were formed. Sonicated chromatin 
was diluted in 5 volumes of dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.0). The immuno-complexes were 
precipitated using antibodies against PPARα, STAT1, STAT3 or STAT6 or normal 
serum IgG (sc-9000, sc-592, sc-482, sc-981, sc-2027, Santa Cruz Biotechnologies). 
Precipitated complexes were reverse cross-linked and proteins digested with 
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proteinase K (Fermentas) overnight at 65 °C. DNA fragments were purified using the 
Affymetrix GeneChIP Clean-up module. Purified DNA was used for qPCR and ChIP-
chip analysis. ChIP experiments were run in quadruplicate.
ChIP-chip 
To obtain sufficient DNA for hybridization, purified ChIP DNA was amplified and 
reamplified with the WGA (re)amplification kit (Sigma-Aldrich). Amplified DNA was 
fragmented with DNAse I to approximately 50 bp fragments. The fragments were 
labeled with biotin according to Affymetrix instructions. Biotinylated DNA fragments 
were hybridized to Human Promoter 1.0R Arrays (Affymetrix). Arrays were washed 
and scanned according to instructions from manufacturer. Arrays were run in 
quadruplicate for both untreated and GW7647 treated cells. 
Quantitative real-time PCR 
Quantitative real-time PCR was performed on enriched regions of LPIN1 and 
AGPAT9. Equal amounts of amplified ChIP material was used and measurements 
were performed on the iCycler (BioRad) using platinum Taq polymerase 
(Invitrogen) and the double stranded DNA dye SYBR green. The following 
primers where used: LPIN1: sense primer 5’-ATTGGGGGTGTTGTGGTATG-’3 
and anti-sense primer 5’-ATAACAAATGCTGGCAAACG-’3. AGPAT9: 
sense prime5’-CATCTAATACACAAACCAAGG-’3 and anti-sense 
primer 5’-AAGCCAAACAAAGACTATTCG-’3. HMGCR: sense primer 
5’-ACGCTGATTTGGGTCTATGG-‘3 and anti-sense primer 5’- 
GTGTAAATGGCTCCGGTCAC-’3. qPCRs were performed in duplicate and on all 
ChIP samples used for ChIP-Chip . Other primer sequences are available upon 
request.
Data analysis ChIP-chip 
Affymetrix microarray CEL files were acquired and normalized using the Model-based 
analysis of tiling-arrays (MAT) algorithm (159). MAT was also used to identify PPARα 
binding regions induced by GW7647 treatment. Tiling-array probe intensities from 
ChIP performed on HepG2 cells treated for 2 h with GW7647 were compared with 
probe intensities from vehicle-treated HepG2 cells. The analysis was performed with 
a MAT score of 2.4 or higher, which was based on MAT scores found for promoters 
of several known PPARα target genes. The human NCBIv36 (hg18) was used as a 
mapping file. In our analysis we used MaxGap of 400 bp and a Bandwidth of 400 bp.
Transcriptomics
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Treatment of HepG2 cells with GW7647 for gene expression analysis by 
transcriptomics was performed in triplicate. Total RNA was extracted from HepG2 
cells with TRIzol reagent (Invitrogen) and subsequently purified using the SV 
Total RNA Isolation System (Promega). RNA quality was measured on an Agilent 
2100 bioanalyzer (Agilent Technologies) using 6000 Nano Chips according to 
manufacturer’s instructions. RNA was judged as suitable for array hybridization 
only when samples showed intact bands corresponding to the 18S and 28S rRNA 
subunits, displayed no chromosomal peaks or RNA degradation products and had a 
RNA integrity number (RIN) above 8.0. Five micrograms of RNA were used for one 
cycle cRNA synthesis (Affymetrix). Hybridization, washing and scanning of Affymetrix 
human genome 133 2.0 plus arrays was carried out according to standard Affymetrix 
protocols. Scans of the Affymetrix arrays were processed using packages from the 
R/Bioconductor project. Arrays were normalized with quantile normalization and 
expression levels of probe sets were calculated using the Robust Multichip Average 
(RMA) method. Differentially expressed probe sets were identified using Limma and 
genes were considered to be significantly changed when raw q value < 0.05 and 
fold-change > 1.2. 
Characterization of PPARα binding regions
For annotation of the ChIP peaks to adjacent genes, we used the Genomatix tool 
RegionMiner. The genes with the shortest distance to the ChIP enriched binding site 
were selected. For identification of new TF modules the software tool FrameWorker 
was used (160). GW7647-induced PPARα binding regions that were assigned to the 
top 25 differentially regulated genes (both up- and down-regulated) were analyzed. 
The minimal occurrence of a module in the binding regions studied was set at 20% 
and a maximal distance bandwidth variation between the motives was set at 75 bp. 
Another Genomatix tool, ModelInspector, was used to scan all the PPARα binding 
regions linked to GW7647-regulated genes. As a control, we scanned approximately 
all human promoter regions present in the Genomatix promoter database with sizes 
between 1kb and 1.5kb, which corresponds with the average size of the binding 
sites identified by ChIP-chip. We used a two-proportion z-test to analyze significant 
enrichment of modules. Samples with p-values values below 0.05 were considered 
significantly different.
Motif analysis
To investigate the presence of de novo DNA motifs, the top 25 PPARα binding 
regions linked to up- or down-regulated genes were loaded into the MEME tool (http://
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meme.sdsc.edu/meme4_1/cgi-bin/meme.cgi). The length for the output motif was 
varied between 12 and 20 bp. Enriched matrixes of output motifs were compared to 
existing motif matrixes available in both the TRANSFAC and the JASPAR database 
with the use of the STAMP tool (http://www.benoslab.pitt.edu/stamp/index.php).
Results
Mapping of PPARα binding regions to adjacent transcripts 
PPARα represents a ligand-induced TF that in the absence of ligand does not seem to 
act as transcriptional repressor, unlike several other nuclear receptors (161). For the 
analysis presented here we assumed that induction of PPARα target gene expression 
by PPARα ligand is associated with increased binding of PPARα to the DNA, which is 
supported by ample experimental data (162-167). Therefore, to identify the complete 
repertoire of hepatic PPARα target genes, we treated HepG2 cells with the synthetic 
ligand GW7647 for 2 h and performed ChIP-chip analysis using an antibody against 
PPARα, with vehicle-treated HepG2 cells serving as control. After amplification and 
fluorescent labeling, the immunoprecipitated chromatin templates were hybridized to 
Affymetrix human promoter tiling arrays. These arrays cover promoter regions of 7.5 
kb upstream and 2.5 kb downstream of the transcription start site (TSS). Statistical 
analysis of four replicate experiments provided evidence for increased binding of 
PPARα to 4220 binding regions in response to treatment with GW7647. 
We used the Genomatix tool RegionMiner to map the genes closest to the 4220 
GW7647-induced PPARα binding regions in four genomic directions and selected 
the gene with the shortest distance to the binding region. The 4220 PPARα binding 
regions were linked to 3670 unique genes, of which 2875 were present on the 
expression arrays used for gene expression analysis. Analogous to other nuclear 
receptors, PPARα binding regions showed a bias towards the TSS (Figure 1A) 
(87,89,90,168). To further analyze the location of PPARα binding regions, the online 
tool PinkThing (http://pinkthing.cmbi.ru.nl/cgi-bin/index50.pl) was used, which 
categorizes binding regions based on distance relative to the TSS (Figure 1B). We 
found that 46% of the binding regions were located within introns, which matches 
very well with a similar analysis done for PPARγ (84). Since we used promoter 
arrays, binding regions located to introns are in most cases present in the first intron. 
It is possible that some of these intronic binding regions actually surround the TSS 
of an alternative splice variant of a gene. Most other binding regions were identified 
upstream of the TSS with 26% within 5 kb and 11% between 5 and 25 kb. The more 
distal binding regions are not covered by promoter tiling arrays and therefore binding 
regions were not expected for the categories 3’ far (5-25 kb) and distant (> 25 kb). 
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Hence, the 1% and 2% of binding regions located to the 3’ far and distant categories, 
respectively, likely reflect misclassification by the PinkThing tool.
Several genes that are established targets of PPARα, such as SULT2A1, ACOX1, 
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Figure 1: Mapping of PPARα binding regions enriched upon GW7647 treatment. (A) Positional 
distribution of all identified PPARα binding regions relative to TSSs of the nearest gene. (B) Identification 
of the genomic location of PPARα binding regions using PinkThing. The following classification criteria 
were used: distant (> 25 kb), 5’ far (25-5 kb), 5’ near (5-0 kb), intron (intronic), exon (exonic), 3’ near (0-5 
kb) and 3’ far (5-15 kb). (C) Enrichment of promoter regions in PPARα target genes. Enriched ChIP-chip 
signals were visualized using Affymetrix Integrated Genome Browser. Coverage of promoter tiling array 
is indicated in red, repetitive sequences in black, and conserved sequence in blue. PPARα target genes 
SULT2A1, ACOX1, IGFBP1, ACADL, CD36 and G0S2 all show positive enrichment within promoter 
regions. No enrichment is observed in the promoter of ANGPTL4 as the known PPRE is present within 
the (non-covered) intron 3.
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ACADL, CD36, IGFBP1, and G0S2 (129,167,169-173), showed GW7647-induced 
PPARα binding regions in the promoter (Figure 1C). However, many other known 
PPARα target genes did not show any ligand-induced binding regions in their promoter. 
For these genes, PPARα is likely bound to a binding site not covered by the promoter 
array or, less likely, their PPRE may be located in repetitive sequences, which are 
excluded from Affymetrix human promoter tiling arrays using RepeatMasker. For 
example, the PPARα target gene ANGPTL4 carries a ligand-induced PPARα binding 
site in the third intron (164), which is out of the range of 2.5 kb downstream of 
the TSS covered by the array. As a result, no significant peak is present within the 
ANGPTL4 promoter (Figure 1C). Finally, it cannot be excluded that for some PPAR 
targets the degree of promoter occupancy by PPARα is not influenced by PPARα 
agonist and therefore no signals are detected, since our analysis concentrated on 
GW7647-induced PPARα binding regions. 
Overlap between ChIP-chip and expression array 
To investigate the relation between genes assigned to a GW7647-induced PPARα 
binding region and expression of that particular gene, we performed expression 
microarray analysis on HepG2 cells treated with GW7647 for 6 h. Confirming 
activation of PPARα, established PPARα targets CYP1A1, ADFP and TRIB3 were 
significantly induced by GW7647 (Figure 2A). Genes were considered significantly 
regulated if the mean fold change exceeded 1.2 and q-value < 0.05. The low cut-
off for fold change was used because the magnitude of induction of PPARα target 
genes in HepG2 cells is limited. Using these criteria 555 genes were differentially 
regulated after 6 h GW7647 treatment (Figure 2B). Slightly more genes were up-
regulated than down-regulated. Differentially regulated genes were compared with 
the genes assigned to the GW7647-induced PPARα binding regions. It was found 
that 54 genes up-regulated by 6 h GW7647 treatment were linked to at least one 
PPARα binding region, representing 17.8% of all up-regulated genes (Figure 2C). 
In comparison, 16.2% of all genes on the expression array were linked to a PPARα 
binding region, which indicates that genes up-regulated by GW7647 showed minimal 
enrichment for PPARα binding. Surprisingly, a PPARα binding region was also linked 
to 46 genes down-regulated by 6 h treatment with GW7647, representing 18.3% 
of all down-regulated genes (Figure 2C). Expression of the far majority of genes 
assigned to a GW7647-induced PPARα binding region was not altered by GW7647 
treatment. 
With the use of the Genomatix tool RegionMiner, the PPARα binding regions linked 
to differentially expressed genes were scanned for the presence of a V$PERO 
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Figure 2: Overlap between GW7647-induced PPARα binding and GW7647-induced changes in 
expression. (A) Significant induction of PPARα targets by GW7647 treatment. (B) Number of genes 
significantly altered upon GW7647 treatment as determined by microarray analysis using criteria: fold 
change > 1.2 and q-value < 0.05. (C) Overlap between genes assigned to GW7647-induced PPARα 
binding regions and genes altered after treatment with GW7647 as determined by transcriptomics. (D) 
Percentage of GW7647-induced PPARα binding regions linked to either up- or down-regulated genes 
that contain at least one V$PERO site, as determined using Genomatix. Similar analysis was done for all 
GW7647-induced PPARα binding regions as well as a control set of promoter regions in the Genomatix 
promoter database with similar size range as the binding regions identified by ChIP-chip (1000bp -1500bp).
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site, which represents a PPRE matrix created by Genomatix (160). At least one 
V$PERO site was present in 81% and 80% of the PPARα binding regions linked 
to respectively the significantly up- or down-regulated genes (Figure 2D). Similarly, 
76% of all PPARα binding regions identified by ChIP-chip contained a V$PERO site. 
In contrast, only 66% of control promoter regions contained a V$PERO site, for which 
we selected promoter regions in the Genomatix promoter database with similar size 
range as the binding regions identified by ChIP-chip (1000bp -1500bp). These data 
suggest modest enrichment of PPARα binding regions for PPREs predicted with the 
V$PERO matrix.
Five genes out of 54 genes that were linked to a GW7647-induced PPARα binding 
region (Figure 3A and data not shown) and were up-regulated by GW7647 (Figure 
3B) are direct target genes of the SREBP transcription factors:  HMGCS1, HMGCR, 
FDFT1, SC4MOL, and LPIN1, while  AGPAT9 is a candidate target gene based on its 
role in triacylglycerol synthesis. Enrichment by GW7647 treatment of PPARα binding 
regions linked to LPIN1, AGPAT9 and HMGCR was confirmed by normal ChIP and 
qPCR (Figure 3C). As expression of several other established SREBP target genes 
was also upregulated by GW7647 (Figure 3D) (174), these data suggest possible 
cross-talk between PPARα and SREBP signaling.
Motifs and module searches
To search for specific DNA motifs in GW7647-induced PPARα binding regions we 
performed a de novo motif search with MEME (http://meme.sdsc.edu/meme4_1/
cgi-bin/meme.cgi). For this analysis we used the binding regions of the 25 most 
significantly up-regulated genes that were assigned to a GW7647-induced PPARα 
binding site (Figure 4). Identified motifs were compared to the two major motif 
databases TRANSFAC and JASPAR to search for similarities to existing TF binding 
motifs using STAMP (http://www.benoslab.pitt.edu/stamp/index.php). One of the 
identified motifs matched the PPARα-RXRα motif in the TRANSFAC database. 
While the classical AGGTCA motif of a PPRE was present, a clear DR1-type tandem 
repeat was not found. This is in line with the earlier findings indicating that the PPRE 
5’ motif is less conserved than the 3’ motif (83,84), suggesting that the site we found 
is most likely a 3’ motif. A second motif had a similarity hit with the C/EBPα motif in 
the JASPAR database, indicating that C/EBPα motif is enriched in PPARα binding 
regions. Interestingly, the C/EBPα motif was recently shown to be enriched in PPARγ 
binding regions and important for regulation of PPARγ target genes (86). 
TFs often work in conjunction with other TFs to regulate DNA transcription. 
Accordingly, we examined whether other TF binding motifs are enriched together 
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Figure 3: Cross-talk between PPARα- and SREBP-dependent gene regulation. (A) Enriched ChIP-
chip signals for HMGCS1, HMGCR, LPIN1 and AGPAT9 genes were visualized using Affymetrix Integrated 
Genome Browser. Coverage of promoter tiling array is indicated in red, repetitive sequences in black, and 
conserved sequences in blue. (B) Gene expression changes after 6 hours PPARα agonist treatment of 
5 direct SREBP target genes and possible SREBP target gene AGPAT9. A GW7647-induced PPARα 
binding region was assigned to each of these genes. Significant differences are indicated with an asterisk 
(Student’s T test, p < 0.05). (C) Transcriptional upregulation of selected SREBP1 target genes involved in 
lipogenesis after 6 hours PPARα agonist treatment represented as a heat map. (D) Enriched DNA binding 
of PPARα to promoter regions of LPIN1, AGPAT9 and HMGCR after 2 hours GW7647 treatment, verified 
by ChIP-qPCR using primers designed within the binding region found by ChIP-Chip.
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with the PPAR binding motif within the set of GW7647-induced PPARα binding regions 
linked to up- or down-regulated genes, using the Genomatix tool Frameworker. The 
PPAR matrix V$PERO was set and screening was performed for binding motifs 
of other TFs. Within the binding regions of the 25 most significantly up-regulated 
genes linked to a GW7647-induced PPARα binding region, we identified a highly 
significant (p = 6.94x10-8) module composed of the TATA binding protein (TBP, 
O$TBP) in combination with the PPAR binding motif V$PERO (Figure 5A). Within 
the binding regions of the 25 most significantly down-regulated genes linked to 
a GW7647-induced PPARα binding region, we identified a highly significant (p = 
1.04x10-8) module composed of the binding motif for the TF Signal Transducers 
and Activators of Transcription (STAT) family (V$STAT) together with V$PERO 
(Figure 5A). To further analyze for the presence of these specific modules, we used 
ModelInspector to scan all the PPARα binding regions linked to GW7647-regulated 
genes. As a control, we also scanned all human promoter areas present in the 
Genomatix promoter database with a size between 1kb and 1.5kb. As shown in 
figure 5B, the module STAT-PERO is significantly enriched in the binding regions 
linked to genes that are down-regulated after 6 h GW7647 treatment compared to 
binding regions linked to genes up-regulated by GW7647 treatment and to all human 
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Figure 4: De novo motif analysis. GW7647-induced PPARα binding regions were screened for specific 
DNA motifs via de novo motif search using MEME. The binding regions of the 25 most significantly up-
regulated genes assigned to GW7647-induced PPARα binding regions were analyzed. Significantly 
enriched motifs were compared with motif databases TRANSFAC as well as JASPAR with the use of 
STAMP. Similarity scores with known TF binding regions are expressed by E-values. One motif identified 
showed similarity to a PPARα motif within the TRANSFAC database, another motif identified showed 
similarity to the C/EBPα motif in the JASPAR database. 
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Figure 5: Enrichment of TF modules in PPARα binding regions. (A) The binding regions of the 25 most 
significantly up-regulated genes assigned to GW7647-induced PPARα binding regions were analyzed 
for TF modules using the Genomatix tool Frameworker. Two modules were identified: TBP-PERO and 
STAT-PERO in the binding regions linked to up- or down-regulated genes, respectively. (B) The modules 
TBP-PERO and STAT-PERO were scanned for the relative presence in all GW7647-induced PPARα 
binding regions located near transcriptional regulated as well as all human promoter regions present in 
the Genomatix database. A two-proportion z-test was used to analyze significant enrichment of modules. 
P-values values below 0.05 were considered significantly different. (C) Loss of DNA binding by STAT3 
and STAT1 upon PPARα activation. HepG2 cells were treated with GW7647 for 2 h and ChIP performed 
using antibodies against STAT3, STAT1 and STAT6 with vehicle-treated HepG2 cells serving as control. 
Precipitated chromatin was subsequently amplified using primers around the predicted STAT-PERO site 
found in 4 genes that were linked to a GW7647-induced PPARα binding region and were down-regulated 
by GW7647.
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promoter regions present in the Genomatix promoter database. In fact, the STAT-
PERO module was found in eight out of 46 genes that were linked to a GW7647-
induced PPARα binding region and were down-regulated by GW7647. Similarly, the 
TBP-PERO module is significantly enriched in binding regions linked to up-regulated 
genes compared to binding regions linked to down-regulated genes and all human 
promoter regions. These results suggest interaction between PPARα and STAT in 
PPARα-mediated transcriptional repression and interaction between PPARα and 
TBP in PPARα-mediated transcriptional activation.
Members of the STAT family bind to similar DNA sequences. Expression profiling 
indicated that expression of STAT3 was highest in HepG2 cells, followed by STAT1 
and STAT6 (data not shown). Accordingly, we focused on those three proteins to 
experimentally validate the suggested interaction between PPARα and STATs 
on the promoter of the aforementioned 8 genes. HepG2 cells were treated with 
GW7647 for 2 h and ChIP performed using antibodies against STAT3, STAT1 and 
STAT6 with vehicle-treated HepG2 cells serving as control. Precipitated chromatin 
was subsequently amplified using primers around the predicted STAT-PERO site. 
Consistent with interaction between PPARα and STATs, for 7 out of 8 genes STAT1 
was released in response to GW7647 treatment (Figure 5C), although the result was 
not always statistically significant. A similar picture emerged for STAT3. In contrast, 
STAT6 showed minor binding which generally was not altered by GW7647. These 
data show that PPARα activation and DNA binding causes the release of STAT3 and 
STAT1 from gene promoters concurrent with down-regulation of gene expression. 
Biological clustering
Finally, within up-regulated genes that were assigned to GW7647-induced PPARα 
binding regions we analyzed for functional biological clusters using DAVID (http://
niaid.abcc.ncifcrf.gov/home.jsp). We found significant over-representation of genes 
in the biological cluster of sterol and lipid biosynthetic process (Table 1), in line with 
binding of PPARα to the putative promoter of several SREBP targets. Within down-
regulated genes that were assigned to GW7647-induced PPARα binding regions we 
found significant over-representation of genes in the biological cluster of humoral 
and innate immune response, which is consistent with the known suppressive effect 
of PPARα on inflammation (Table 1). 
Discussion
It is well established that PPARα is a major transcriptional regulator of fatty acid 
metabolism in liver. Numerous genes involved in fatty acid oxidation and other 
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metabolic processes have been identified as direct target genes of PPARα in mouse, 
characterized by the presence of a functional PPRE (14,172). In the past few years, 
genomic binding regions of several nuclear receptors including PPARγ have been 
mapped (84,86). However, no reports are available that were aimed at mapping the 
binding regions for PPARα. In our study we used ChIP-chip to investigate ligand-
induced PPARα binding to genomic regions within HepG2 human hepatoma cells.
A total number of 4220 ligand-induced PPARα binding regions were identified, which 
were assigned to 3670 unique genes. Although this number may appear exceptionally 
high, the threshold for inclusion was set based on inspection of a number of known 
PPARα binding regions. Our assignment of PPARα binding regions relative to the 
nearest gene showed a distance-to-TSS distribution centered around the TSS. 
Categorizing these distances revealed that the majority of the binding regions are 
located within an intron or in the 5’ proximal region. These findings are in line with 
various studies showing that TF binding regions are normally distributed around the 
TSS (87,175-177). The preponderance of binding regions around the TSS may also 
reflect DNA looping allowing nuclear receptors bound to distal sites to contact the 
basal transcription machinery. Previous genome-wide analysis of ERα and PPARγ 
binding sites indicate that a large fraction of the binding regions are located distal from 
the TSS (86,89). Since we used promoter tiling arrays, our analysis was unable to 
detect binding to distant binding regions. Some of these distal elements have been 
Sterol biosynthetic process
Lipid biosynthetic process
Apoptosis
Developmental process
1.1E-4
1.9E-2
4.0E-2
2.2E-2
Biological process p-value
Upregulated genes
Humoral immune response 1.2E-2
Biological process p-value
Downregulated genes
gamma-Hexachlorocyclohexane
degradation  
1,8E-3 
Table 1: Enrichment of biological processes in GW7647-regulated genes assigned to a PPARα 
binding region. Up-regulated genes assigned to GW7647-induced PPARα binding regions were 
analyzed for functional biological clusters using DAVID.
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shown to indeed function as functional PPREs (136,164,178,179). However, many 
distant binding regions are likely misclassified and are actually located in proximal 
promoters of new transcripts (73,180). Furthermore, many regions identified by 
ChIP-based methods do not show any effect on the expression of the gene closest 
to that region. These issues raise questions about the functional relevance of many 
of these binding regions (181). 
We compared our ChIP-chip data with mRNA expression data collected by expression 
microarray and found that about 18% of the genes induced by ligand were linked to 
a GW7647-induced PPARα binding region. The other 82% may not represent direct 
target genes, may bind PPARα equally in absence and presence of ligand, may 
bind PPARα via a site located outside the range covered by the array, or the actual 
PPARα binding region was linked to a different gene. 
Importantly, the overwhelming majority of PPARα binding regions were linked to 
genes that were not significantly altered upon GW7647 treatment, even after more 
prolonged treatment (data not shown). It is well recognized that the majority of binding 
regions found by ChIP-chip or ChIP-Seq experiments do not have any effect on 
the genes they were linked to (181). This could be partially due to miss-annotation, 
which is inevitable when assigning to the nearest gene. However, since the number 
of GW7647-induced binding regions far exceeds the number of GW7647-regulated 
genes many regions must bind PPARα without any impact on gene regulation. These 
findings are consistent with the “scanning model” proposed for PPARs, which states 
that PPARs scan the genome and transiently bind to PPRE-like sequences without 
inducing any transcription. According to this model, PPARs only start transcription 
upon binding to a bona fide PPRE (88). What distinguishes a bona fide PPRE from 
a PPRE-like sequence is not well understood. Recent ChIP-chip studies on several 
TFs revealed that clusters of different TF binding elements are enriched in proximity 
of the binding region for the TF under study (86,89,90,182-184). We searched for 
these types of clusters in PPARα binding regions that were linked to differentially 
regulated genes and found several modules of TF binding elements in combination 
with a PPRE. In PPARα binding regions linked to up-regulated genes we found 
enrichment for a module composed of the binding sequence for TBP together with 
that of PPARα. Since TBP is an important component of the basal transcriptional 
machinery, this finding suggests binding of PPARα adjacent to the core promoter. 
A second interesting module we found was a combination of a PPARα binding 
sequence and a STAT binding sequence, which was strongly enriched in PPARα 
binding regions linked to genes that were down-regulated by PPARα activation. 
STAT transcription factors function downstream in the signaling pathway of a large 
62
Chapter 3
number of cytokines, growth factors, and hormones (185). Follow-up analysis by 
normal ChIP showed that binding of STAT3 and also STAT1 to these genes was 
reduced upon GW7647 treatment. Our data suggest that loss of STAT binding is 
dependent on binding of PPARα adjacent to the STAT binding site. Inhibition of STAT-
dependent transcriptional activity and DNA binding has been previously documented 
for PPARγ and PPARβ/σ (91,186-190), and may also partially account for the anti-
inflammatory action of PPARα activation (91,186-190). Overall, down-regulation of 
gene expression by PPARα activation in HepG2 cells may be partially mediated by 
interfering with binding of STAT3 and STAT1 to the DNA. 
Using Genomatix we found that at least one V$PERO site was present in 81% of the 
PPARα binding regions linked to the significantly up-regulated genes. A similarly high 
percentage was found for all the GW7647-induced PPARα binding regions resulting 
from the ChIP-chip analysis. While this result would suggest that the majority of 
PPAR binding detected by our ChIP-chip analysis conforms to the general paradigm 
of PPRE-dependent DNA binding, it should be emphasized that V$PERO sites are 
found at relatively high frequency throughout the genome and may have limited 
specificity. As ChIP is capable of detecting any type of binding of PPARα to DNA, 
which includes indirect binding via other TFs, it is difficult to provide a good estimate 
of the relative importance of PPRE-dependent and PPRE-independent binding to 
DNA. Binding to DNA of transcription factors in the absence of a consensus motif 
has been a common observation in recent ChIP-chip and ChIP-seq studies. Several 
explanation may account for this apparent discrepancy as elaborated by Farnham 
(181), including binding at a distal site that contains a consensus motif and looping 
to the site in question through protein–protein interactions; ‘piggyback’ binding that 
is mediated by protein–protein interactions with a second factor and that does not 
involve the DNA binding domain of the first factor; or assisted binding to a site that is 
similar to the consensus site, which is enhanced by protein–protein interaction with 
another site specific DNA binding factor or with a specifically modified histone.
Within the set of GW7647-induced PPARα binding regions linked to up-regulated 
genes, no established direct PPARα targets were present. One problem is that 
HepG2 cells, despite their broad use, poorly reflect gene regulation by PPARα 
in other cultured cells such as rat FAO hepatoma cells (153) and primary human 
hepatocytes. Indeed, we found remarkably little overlap in gene regulation by PPARα 
agonist between HepG2 cells and primary human hepatocytes (van der Meer et 
al., in preparation). Unfortunately, ChIP-chip analysis in primary human hepatocytes 
is practically unfeasible. Clearly, an ideal system to study PPARα-dependent gene 
regulation in human is lacking.
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The transcription factors SREBP-1 and SREBP-2 are important regulators of hepatic 
lipid and cholesterol synthesis (191). Previously, it was shown that PPARα is involved 
in the normal circadian regulation of target genes of SREBPs, including HMGCR 
(192). Furthermore, synthetic PPARα agonists were found to induce expression of 
SREBP targets in liver, which was completely abolished in SREBP-1-/- mice and 
PPARα-/- mice (193)(194). The effect of PPARα agonists on SREBP targets was 
attributed to increased activation of SREBP-1c via enhanced proteolytic cleavage, 
and was not mediated by changes in SREBP-1 mRNA (193). In the present paper 
we find induction of expression of several SREBP targets by PPARα activation in 
human hepatoma HepG2 cells. Furthermore, in these cells PPARα agonist stimulated 
binding of PPARα to the putative promoter of SREBP targets HMGCS1, HMGCR, 
FDFT1, SC4MOL and LPIN1 genes. These data suggest important cross-talk 
between PPARα and SREBP signaling. The exact nature of the cross-talk requires 
further investigation but one possibility is that PPARα is recruited to promoters of 
SREBP targets via direct physical interaction with SREBP. It could be envisioned that 
through this interaction PPARα may promote SREBP activity, perhaps by assisting 
with recruitment of transcriptional co-activators. In addition to the above mentioned 
genes, a PPARα binding region was assigned to the AGPAT9 gene, which can be 
suspected to be a SREBP target as well. LPIN1 and AGPAT9 encode enzymes that 
catalyze the second and third step in the triacylglycerol synthesis pathway. So far, 
several genes involved in either fatty acid or triacylglycerol synthesis have been 
identified as direct PPARα target genes including Δ5 and Δ6 desaturases and malic 
enzyme (summarized in (14,15)). Indeed, the involvement of PPARα in lipogenesis 
appears to be much more extensive that previously understood (195). Although 
this notion is seemingly at odds with increased hepatic TG observed upon PPARα 
deletion, regulation of fatty acid metabolism by PPARα is probably more subtle than 
generally envisioned. According to data presented here, PPARα may also indirectly 
impact lipid biosynthesis via cross-talk with SREBP. 
In aggregate, it can be concluded that ChIP-chip represents a powerful tool to 
investigate whole genome binding of PPARα. Our data indicate that PPARα agonists 
trigger the binding of PPARα to a large number of genomic sites and provide novel 
insights into the mechanisms of PPARα-dependent transcriptional regulation.
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Abbreviations
ACADL, Acyl-Coenzyme A dehydrogenase, long chain;
ACOX1, Acyl-Coenzyme A oxidase 1, palmitoyl;
AGPAT9, 1-Acylglycerol-3-phosphate O-acyltransferase 9;
ANGPTL4, Angiopoietin-like 4;
AR, Androgen receptor;
C/EBP, CCAAT/enhancer binding protein;
CD36, CD36 molecule;
ChIP, Chromatin immunoprecipitation;
ChIP-chip, Chromatin immunoprecipitation followed by microarray analysis;
ChIP-Seq, Chromatin immunoprecipitation followed by sequencing;
DAVID, Database for Annotation, Visualization and Integrated Discovery;
DMEM, Dulbecco’s modified Eagle’s medium;
DMSO, Dimethyl sulfoxide;
DR1, Direct repeat spaced by one nucleotide;
ERα, Estrogen receptor alpha;
FBS, Fetal bovine serum;
G0S2, G0/G1switch 2;
GR, Glucocorticoid receptor; 
GW7647, 2-(4-(2-(1-cyclohexanebutyl-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid;
HepG2, Human hepatocellular liver carcinoma cell line;
HMGCS1, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1;
IGFBP1, Insulin-like growth factor binding protein 1;
LPIN1, Lipin 1;
MAT, Model-based analysis of tiling-arrays;
MEME, Multiple Em for Motif Elucidation;
O$, Other;
OCT1, Octamer-binding transcription factor 1;
PBS, Phosphate-buffered saline;
PERO, Peroxisome proliferator-activated receptor (genomatix family);
PGC-1α, Peroxisome proliferative activated receptor gamma co-activator 1 alpha;
PPAR, Peroxisome proliferator-activated receptor;
PPRE, PPAR response element;
qPCR, Quantitative polymerase chain reaction;
RXR, Retinoid X receptor;
STAT, Signal transducers and activators of transcription; 
SULT2A1, Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone; (DHEA)-preferring, member 
1;
TBP, TATA binding protein;
TF, Transcription factor;
TSS, Transcription start site;
V$, Vertebrates; 
VLDL, Very low density lipoprotein receptor;
WGA, Whole genome amplification;
Wy14,643, Pirinixic acid;
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Abstract
PPARα is an important transcriptional regulator of hepatic lipid metabolism. Most of 
the research on PPARα in liver has been carried out in mice or using hepatocyte cell 
lines. However, to what extent results from cell lines properly reflect the function of 
PPARα remains to be established. The aim of the present study was to compare the 
transcriptional response to PPARα activation between HepG2 and primary human 
hepatocytes, the latter being considered as the gold standard. Our transcriptomics 
analysis reveals that the response to PPARα agonist is remarkably dissimilar 
between HepG2 cells and primary human hepatocytes. While expression of many 
established PPARα targets shows significant induction by PPARα activation in primary 
hepatocytes, this is much less the case in HepG2 cells which are characterized by 
marginal induction of a limited number of PPARα targets. This set of PPARα targets 
includes CYP1A1, CPT1A, ADFP, and TRIB3. Instead, PPARα activation in HepG2 
cells leads to induction of stress response pathways. In conclusion, our results show 
that HepG2 cells relatively poorly reflect the established function of PPARα in lipid 
metabolism, in contrast to primary human hepatocytes. Accordingly, with respect to 
PPARα function, caution should be exercised when extrapolating data from HepG2 
cells to human liver.
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Introduction
Peroxisome proliferators activated receptors (PPARs) are ligand inducible nuclear 
receptors that play a major role in the regulation of cellular energy homeostasis. 
Three PPARs  have been identified: PPARα (NR1C1), PPARβ/σ (NR1C2) and 
PPARγ (NR1C3). PPARs are activated by fatty acids and fatty acid derivates, as 
well as by a diverse group of synthetic compounds (59,196,197). PPARα is well 
expressed in liver and other tissues with a high rate of fatty acid catabolism such 
as heart and skeletal muscle (14). and regulates the transcription of numerous 
genes involved in fatty acid oxidation, fatty acid uptake and transport, ketogenesis, 
gluconeogenesis, amino acid metabolism and inflammation. Compared to PPARα, 
PPARβ/σ is expressed in a broader range of tissue including brain, small intestine, 
heart, skeletal muscle, adipose and skin tissue (12,29,198). Recent studies have 
linked PPARβ/σ to regulation of glucose homeostasis, fatty acid metabolism, wound 
healing, and inflammation ((30-33). The third isotype, PPARγ, is highly expressed 
in adipose tissue where it is involved in adipose cell differentiation and lipid storage 
(199). In contrast to the classical steroid receptors, PPARs form heterodimers with 
another nuclear receptor named Retinoid X Receptor (RXR). According to the 
traditional view, target genes of PPARs are characterized by a PPAR responsive 
element (PPRE) in their promoter region that is capable of binding PPAR/RXR 
heterodimers. However, recent studies suggest that many PPAR binding sites are 
located distant from the transcription start site and that regulation may be conferred 
by DNA looping (84,86).. Upon ligand binding to PPAR, a conformational change of 
the receptor results in the dissociation of corepressor proteins and the binding of 
several coactivator proteins which ultimately results in initiation of transcription of a 
target gene (88).  
Because PPARα is expressed at high level in liver, lots of research has been carried 
out on the role of PPARα in the liver. Many of these studies have made use of 
mouse models due to the relative ease to obtain whole liver tissue directly from mice 
as well as the possibility to perform in vivo gene targeting. However the obvious 
drawbacks of rodent models are differences in the regulation of biological processes 
between rodents and human. Consequently, extrapolation of data from rodent 
models to the human situation can be problematic. For example, the hepatomegaly 
and peroxisome proliferation observed in response to PPARα activation in mouse 
and rat is not observed in human cells (200). However, in contrast to mouse tissue, 
whole human liver tissue and primary human hepatocytes are not widely available 
and are expensive, thereby limiting their use. Instead, much research is performed 
using liver derived and immortalized cell-lines such as the hepatoma derived cell-
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line HepG2. Several studies have used this cell line to investigate the role of PPARα 
in human liver cells (130,201-204).  HepG2 cells are derived from a hepatoma in 
15 year old Caucasian male (205). The advantage of this immortalized cell line is 
the almost unlimited availability and reduced variability compared to donor-derived 
primary hepatocytes. However, differences in this cell line in comparison to primary 
hepatocytes would be expected due to its transformation from a differentiated and 
low proliferating hepatocyte to a highly proliferating cancer cell line. Previous studies 
comparing the two cell systems have mainly been focused on the difference in 
responsiveness to toxicological stimuli and biotransformation in the two celltypes 
(206-213).  Furthermore, previous studies addressed differences in basal gene 
expression profiles between HepG2 cells and primary hepatocytes using micro array 
technology (214,215). These studies show alterations in gene expression in HepG2 
cells that are related to its transformation to a cancer cell line, which includes genes 
involved in cell cycle and check-point control as well as genes involved in cell death, 
lipid metabolism, transport and xenobiotic metabolism. Surprisingly, Harris et al. also 
reported loss of gene expression of several genes in primary hepatocytes that were 
actually expressed in whole liver and HepG2 cells, suggesting that is some cases 
HepG2 cells would be a preferred human liver cell model. To date, no systematic effort 
has been performed comparing the transcriptional response to PPARα activation in 
HepG2 cells and human primary hepatocytes. 
Material and methods
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Figure 1: Expressional changes in HepG2 cells and primary hepatocytes upon PPARα activation. 
Bars indicate total genes regulated at either 6 hours or 24 hours of PPARα agonist treatment with the upper 
part representing the number of upregulated genes and the bottom part the number of downregulated 
genes. Genes were considered significantly changed when fold changes were >1.2 for upregulated genes 
and <-1.2 for downregulated genes as well as a q-value <0.05
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Cell culture
HepG2 cells were grown in phenol red free Dulbecco’s modified medium (DMEM) 
emented with 10% fetal bovine serum (FBS), glutamate and antibiotics. Cells were 
kept at 37 °C and 5% CO 2. Cells were split the day before experiments. Human 
hepatocytes and Hepatocyte Culture Medium Bulletkit were purchased from 
Lonza Bioscience (Verviers, Belgium). Primary hepatocytes were isolated from 
surgical liver biopsies obtained from six individual donors who underwent surgery 
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132 34 709 50 8 506
Primary hepatocytes HepG2 Primary hepatocytes HepG2
Primary hepatocytes HepG2 Primary hepatocytes HepG2
6h Upregulated 6h Downregulated
24h Upregulated 24h Downregulated
Figure 2 : Overlap between differential regulated genes in HepG2 cells and primary hepatocytes. 
Venn diagrams represent overlap between either the upregulated genes or downregulated genes in 
HepG2 cells and primary hepatocytes. 
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Figure 3: Principal component analysis of genes expressed in HepG2 cells and primary 
hepatocytes. Principal component (PC) 1 and 2 represent the variation found between the samples after 
either 6 hours or 24 hours PPARα activation. 
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after informed consent was obtained. Hepatocytes were isolated with two-step 
collagenase perfusion method and the viability of the cells was over 80%. Cells were 
plated on collagen-coated six-well plates and filled with maintenance medium. Upon 
arrival of the cells, the medium was discarded and was replaced by Hepatocyte 
Culture Medium (HCM) with additives. Additives included Gentamicin sulphate/
Amphotercin-B, Bovine serum albumin (Fatty acid free), Transferrin, Ascorbic acid, 
Insulin, Epidermal growth factor, Hydrocortisone hemisuccinate.
Transcriptomics
Total RNA was extracted from either HepG2 cells or primary hepatocytes with TRIzol 
reagent (Invitrogen) and subsequently purified using the SV Total RNA Isolation 
System (Promega). RNA quality was measured on an Agilent 2100 bioanalyzer 
(Agilent Technologies) using 6000 Nano Chips according to manufacturer’s 
instructions. RNA was judged as suitable for array hybridization only when samples 
showed intact bands corresponding to the 18S and 28S rRNA subunits, displayed no 
chromosomal peaks or RNA degradation products and had a RNA integrity number 
(RIN) above 8.0. Five micrograms of RNA were used for one cycle cRNA synthesis 
(Affymetrix). Hybridization, washing and scanning of Affymetrix human genome 133 
2.0 plus arrays was carried out according to standard Affymetrix protocols. Scans 
of the Affymetrix arrays were processed using packages from the R/Bioconductor 
project. Arrays were normalized with quantile normalization and expression levels 
of probe sets were calculated using the Robust Multichip Average (RMA) method. 
Differentially expressed probe sets were identified using IBMT and genes were 
considered to be significantly changed when raw q-values were smaller the 0.05 
and fold-change was above 1.2 or below -1.2. 
Comparative analysis
To compare the number of genes regulated in HepG2 cells as well as the number 
of cells in primary hepatocytes a Venn diagram was created with venny (http://
bioinfogp.cnb.csic.es/tools/venny/index.html). Scatterplots were made by plotting all 
expression values of both cell types with the use of the SSPS statistical program. 
For comparison of the top 50 upregulated genes in either HepG2 cells or primary 
hepatocytes together with the expression of these genes in the other cell type 
heatmaps were created based on fold changes with the use of Microsoft Excel. PCA 
scores were obtained from all expression values taken from the arrays of both HepG2 
cells and primary hepatocytes with the use of R package FectoMiner.  Obtained 
PCA scores were plotted using SSPS. To define significant difference between cell 
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groups a one-way ANOVA combined with a turkey post hoc analysis was performed. 
Biological characterization
To characterize genes according to their biological function a Gene Set Enrichment 
Analysis (GSEA) was performed. As a cut off for enriched gene sets the FDR-q value 
was set at <0.25. Enriched gene sets were ordered according to their normalized 
enrichment score (NES).  
Results
To compare PPARα induced gene expression in HepG2 cells and primary human 
hepatocytes, cells were treated with PPARα agonist for 6 or 24 hours and changes 
in gene expression analyzed by microarray. A fold-change threshold of 1.2 and a 
minimal q-value of 0.05 was used. The lower-fold change threshold was chosen 
due to the limited magnitude of gene induction by PPARα agonists in human 
hepatocytes and HepG2 cells. After 6 hours of agonist treatment, 339 genes were 
upregulated and 282 genes downregulated in HepG2 cells, compared to 144 genes 
upregulated and 73 genes downregulated in primary human hepatocytes (Figure 1). 
The difference in number of genes regulated between the two cell systems was even 
more pronounced after 24 hour agonist treatment.
To further study the response to PPARα activation in HepG2 cells and primary 
hepatocytes, the overlap in gene regulation between the two cell systems was 
analyzed. As shown in figure 2, 20 and 34 genes were commonly upregulated in 
both cell types after 6 hours and 24 hour of agonist treatment, respectively.  These 
numbers represent 13.8% and 20.5% of the total number of genes upregulated in 
primary hepatocytes, but only 5.9% and 4.6% of the total number of genes upregulated 
in HepG2 cells after 6 hours and 24 hours of PPARα activation, respectively. Even 
less overlap was observed when examining the genes downregulated upon agonist 
treatment.
To globally compare the gene expression profiles in both cell types, we performed 
principal component analysis (PCA) on the expression values of all genes after 6 or 
24 hours agonist treatment. As shown in figure 3, principal component one (PC1) 
explains 79.8% and 78.5% of the variation in gene expression at 6 and 24 hours, 
respectively. PC1 scores for all primary hepatocyte samples are not significantly 
different. Similarly we observed grouping of PC1 scores for all HepG2 samples without 
any significant changes between the HepG2 samples. However, comparing the PC1 
scores of the two cell types shows a significant difference between the cell types, 
indicating that PC1 explains significant variation between the general expression 
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profiles of the two cell types.  Furthermore, we observed significant separation of 
donor 5 and 6 in principal component two (PC2), indicating a general expression profile 
that is weakly different from the other four donors explained by PC2. Interestingly, 
these two donors are the two 
oldest male donors. PC1 
and PC2 did not explain any 
significant variation caused 
by PPARα agonist treatment 
in either cell type when 
analyzing all expression data 
of both cell types together.
To further compare changes 
in gene expression upon 
PPARα activation between 
HepG2 cells and primary 
hepatocytes, changes in 
gene expression for all genes 
on the array were plotted in 
a scatter diagram (Figure 
4). The results show that 
with the exception of a few 
genes (e.g. KLF10, CYP1A1, 
ADFP), the majority of genes 
regulated were regulated 
specifically in one of the 
cell types. Genes encoding 
for metallothioneins were 
specifically regulated in 
HepG2 cells. In contrast, 
many well described PPARα 
target genes, including 
PDK4, ANGPTL4 and 
FABP1 (164,216-218), were 
regulated specifically in 
human primary hepatocytes.
To further analyze similarities 
in gene regulation between 
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Figure 4: Global gene expression comparison in HepG2 cells 
and primary hepatocytes upon PPARα activation. All expression 
values of all genes were plotted in scatter diagram based on fold 
change after PPARα activation. Selected PPARα target genes are 
indicated as well as some metallothionins specifically regulated in 
HepG2 cells.
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the two cell types, we selected the top 50 upregulated genes in HepG2 cells and 
show the corresponding changes in gene expression in primary hepatocytes. 
Conversely, we selected the top 50 upregulated genes in primary hepatocytes and 
show the corresponding changes in gene expression in HepG2 cells (Figure 5). The 
top 50 genes induced in HepG2 cells show a consistent response between the three 
replicates. Among the genes responding most strongly are several genes coding for 
metallothioneins, which do not show any changes in primary hepatocytes. Similar to 
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Figure 5A: Heatmaps representing top 50 regulated genes in HepG2 cells and primary hepatocytes 
after PPARα agonist treatment. (A) Top 50 significantly upregulated genes in HepG2 cells were 
compared with expressional change of the corresponding gene in primary hepatocytes. 
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the scatter diagram, the results show that very few genes induced by PPARα agonist 
treatment in primary hepatocytes are also regulated in HepG2. Furthermore, the top 
50 upregulated genes in HepG2 very poorly reflects the known role of PPARα in 
lipid metabolism and instead points towards induction of cellular stress response. 
In contrast, in primary hepatocytes a large number of genes within the top 50 of 
upregulated genes are involved in lipid metabolism and represent established PPARα 
targets. These include ANGPTL4, FABP1, PCK1, HMGCS2, S25A20, ACSL3, CPT2 
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Figure 5B: Heatmaps representing top 50 regulated genes in HepG2 cells and primary hepatocytes 
after PPARα agonist treatment. (B) Top 50 genes changed in primary hepatocytes were compared to 
the corresponding gene change in HepG2 cells. Genes were considered upregulated when fold change 
>1.2 and q-value was <0.05.
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and several others. These various types of analyses indicate a poor match between 
the effect of PPARα activation between primary hepatocytes and HepG2 cells. 
Overall, the observed changes in gene expression in HepG2 very poorly resemble 
the role of PPARα in lipid metabolism, and mostly points towards induction of cellular 
stress response. The set of genes robustly induced in both cell types was limited to 
VLDLR, ADFP, CYP1A1, CPT1A, KLF10 and LOC55908. 
These data suggest that HepG2 cells are an inferior model to study PPARα dependent 
gene regulation, especially in relation to its role in lipid metabolism. 
Biological classification
The biological classification of genes specifically upregulated or downregulated in 
either HepG2 cells or primary hepatocytes, or commonly regulated in both cell types 
was investigated using Gene Set Enrichment Analysis (GSEA). A global comparison 
of biological processes regulated in HepG2 cells and primary hepatocytes showed 
a rather low number commonly up regulated pathways in the two cell types after 6 
hours agonist but is slightly better overlap was found after 24 hours agonist (Figure 
6A). The biological process enriched by PPARα agonist in both cell types belonged 
to the classical PPARα-dependent pathway involved in fatty acid beta oxidation. 
Additional enrichment of PPARα related pathways was found among the biological 
processes specifically enriched in primary hepatocytes (Figure 6B). In contrast, 
pathways exclusively upregulated by PPARα agonist in HepG2 cells were related 
to steroid/sterol metabolism (6 hours). Interestingly, the amino acid degradation 
pathway of valine and (iso)leucine was upregulated in both cell types after 24 hours 
PPARα agonist treatment. Previously, amino acid metabolism was shown to be 
downregulated by PPARα in mouse liver (219). A similar analysis was performed 
on genes downregulated after 6 and 24 hours of PPARα stimulation. After 24 hours 
of agonist treatment no pathways were commonly downregulated in both cell types 
(Figure 6A), which is consistent with the minimal overlap observed at the individual 
gene level (Figure 2). Consistent with the known suppressive effect of PPARα on 
inflammation, inflammatory pathways, such as the chemokine and interleukine 
pathways were downregulated by PPARα agonist in both primary hepatocytes and 
HepG2 cells after 6 hours PPARα activation (data not shown).
To further explore differences in gene regulation between HepG2 and primary 
hepatocytes, we compared the expression of several nuclear receptors and co-
activator proteins under basal condition. As shown in figure 7, the expression of 
most nuclear receptors was not very different between the two cell types.  However, 
the nuclear receptors HNF4A,  PPARα and RXRα were more highly expressed in 
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HepG2 cells compared to primary hepatocytes. These data suggest that the minor 
effect of PPARα agonist in HepG2 cells on established PPARα targets and pathways 
is not related to low PPARα expression. Additionally, we compared the expression of 
several coactivators known to be involved in the PPARα dependent gene regulation 
(Figure 7). Whereas MED1, SRC3 and PRIP were much more highly expressed 
in HepG2 cells, CITED2 and PCAF were much more highly expression in primary 
hepatocytes.  
Discussion
Most of the research on PPARα in liver has been carried out in mice or using 
hepatocyte cell lines.  Previously, we addressed the similarities in response to 
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Figure 6: Biological classification of genes regulated in HepG2 cells and primary hepatocytes 
upon PPARα induction. (A) Regulated genes in primary hepatocytes and HepG2 cells were classified 
based on biological function using Geneset Enrichment Analysis (GSEA) and compared. Pathways with 
a FDR-q value below 0.25 were considered enriched. (B) All biological pathways enriched after 6 hours 
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PPARα activation between human and mouse primary hepatocytes (220). Here, 
we concentrate our analysis on the most widely used liver cell line, which is the 
hepatocarcinoma-derived cell line HepG2. Since cell lines often lose functional 
properties compared to the tissue from which they were derived from, it is important 
to investigate the suitability of these cell lines to study PPARα-dependent gene 
regulation. Overall, our data indicate that care should be taken in the use of HepG2 
as a model to study PPARα function in human liver. 
Basal differences in gene expression between HepG2 cells and primary hepatocytes 
have been previously studied using microarrays (214,215). It was found that 31% 
of the genes expressed in HepG2 cells are specific for this cell type, which included 
genes involved in pathways that are expected to be activated in an immortalized cell 
line such as cell cycle control, oncogenes and tumor suppressor genes. Similarly, 
Ligoru et al. found 4306 genes to be differentially expressed between HepG2 cells 
and primary hepatocytes under basal conditions. Again, several of these genes 
are involved in cell cycle regulation and checkpoint control. Surprisingly, Harris et 
al. found several genes to be similarly expressed in HepG2 and whole liver, but 
diminished in primary hepatocytes, indicating that primary hepatocytes may not 
always reflect the in vivo situation better compared to HepG2 cells. 
One previous report compared the transcriptional changes upon PPARα stimulation 
in HepG2 cells to a rat cell line (FAO) using micro array technology (153). Very minor 
overlap in PPARα-dependent gene regulation was observed between the two cell 
lines. Furthermore, very few genes involved in lipid metabolism were induced by 
PPARα activation in HepG2 cells. Remarkably, we could discern little overlap between 
genes regulated by PPARα in HepG2 cells in our study and in the abovementioned 
report.. One possible reason may be differences in the properties of the HepG2 cells 
used  as well as differences in culture conditions.  
Our data show that the total number of genes regulated by PPARα agonist in HepG2 
cells markedly exceeded the number in primary hepatocytes. One likely reason is 
that HepG2 cells are a lot more homogenous and consequently the response to 
PPARα activation is less variable and thus more likely to be statistically significant. 
Indeed, the overall magnitude of fold changes in expression were not noticeably 
different between the two cell types. However, the changes in gene expression upon 
PPARα activation in HepG2 cells poorly reflect the established function of PPARα in 
lipid metabolism. In contrast to primary hepatocytes, only a limited number of known 
PPARα targets were induced by PPARα agonist in HepG2 cells, which included 
CPT1A, ADFP, and TRIB3 (221). Instead, treatment of HepG2 cells with PPARα 
agonist induced the expression of numerous genes involved in stress response 
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pathways including various metallothioneins and DDIT4.
Numerous explanations may account for the differential response to PPARα activation 
between HepG2 cells and primary hepatocytes. Although HepG2 cells and primary 
hepatocytes were grown in different culture medium, it is unlikely that this would 
account for the vast difference in response to PPARα activation. One possibility is 
that genome accessibility is altered in cancer derived cell lines such as HepG2, 
resulting in a differential response to PPARα activation. Another explanation relates 
to differences in overall coactivator expression between the celltypes. For instance, 
expression of  CITED2 and PCAF was significantly higher in primary hepatocytes 
compared to HepG2 cells. Contrary to our expectation, expression of PPARα itself 
was higher in HepG2 cells. Finally, individual genes may respond less in HepG2 cells 
because of mutations in the promoter region. For instance, the PPARα target gene 
PDK4 shows decreased basal expression in HepG2 cells because of a mutation in 
either a SP1 or CBF binding site within its promotor (222), which may account for the 
lack of induction of PDK4 upon PPARα activation..
With respect to downregulation of gene expression by PPARα, which has been 
much less explored mechanistically but likely accounts for a major portion of PPARα 
action,  we found downregulation of several genes involved in acute inflammation 
pathways in HepG2 cells and primary hepatocytes after 6 hours of PPARα activation. 
Previously, studies in intact mouse models have indicated a major role for PPARα in 
governing hepatic and vascular inflammation (14,17). 
In conclusion, our results show that HepG2 cells relatively poorly reflect the 
established function of PPARα in lipid metabolism, in contrast to primary human 
hepatocytes. Accordingly, with respect to PPARα function, caution should be 
exercised when extrapolating data from HepG2 cells to human liver.
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Abstract 
Peroxisome Proliferator-Activator Receptors (PPARs) are ligand inducible transcription 
factors that play an essential role in the regulation of various physiological processes 
including lipid metabolism and inflammation. PPARs regulate transcription of their 
target genes via the formation of heterodimers with the Retinoid X Receptor (RXR) 
and binding to specific DNA sequences called PPAR responsive elements (PPREs). 
The general composition of PPREs include a direct repeat of two hexameric core 
sequence of the consensus AGGTCA which are  spaced by one nucleotide (DR1). 
A number of models have been developed that predict PPAR binding to DNA. The 
majority of these models are based on position weight matrices (PWM) which assigns 
weights to nucleotides based on conservation. Recently, ChIP-chip studies have 
enabled the identification of DNA regions bound by PPARs. These in vivo studies 
have led to the identification of many more PPARα-DNA interactions than genes 
transcriptionally regulated. To explore this relationship between predicted DNA 
binding, in vivo DNA binding and PPARα target gene expression, we compared both 
ChIP-Chip and gene expression data with predicted PPARα binding sites based on 
a PWM for PPAR binding (V$PERO) and the classifier model.  Our data show that 
PPARα binding in vivo and predicted PPARα binding site overlap depends mainly on 
the prediction model used. Whereas V$PERO overlapped with approximately 70% 
of the in vivo found PPARα binding sites, the classifier method showed only about 
30% overlap with the most lenient threshold settings. However, the  classifier showed 
better performance when predicting binding sites linked to genes transcriptionally 
upregulated by PPARα activation. Furthermore,  we identified various transcription 
factor binding site modules coupled to specific binding pattern and gene expression. 
Further research may clarify the functions of these  models in PPARα mediated gene 
regulation.
85
Comparative analysis of in vivo PPARα DNA binding, computational predicted PPARα 
DNA binding and PPARα mediated gene regulation
Introduction 
Nuclear receptors are ligand inducible transcription factors that play an essential 
role in the regulation of various physiological processes including metabolism, 
reproduction, inflammation and development (9). Within the superfamily of nuclear 
receptors one subclass is comprised of the Peroxisome Proliferator-Activated 
Receptors (PPARs) which are particularly involved in fatty acid metabolism and 
glucose homeostasis (10). Three PPAR isotypes have been identified which are 
named PPARα (NR1C1), PPARβ/σ (NR1C2) and PPARγ (NR1C3) (124,125). In 
agreement with their functions in lipid and glucose homeostasis, dysregulation of 
these receptors is linked to diseases such as obesity, cardiovascular disorders and 
diabetes melltus type 2 (195). PPARs regulate transcription of their target genes via 
the formation of heterodimers with the Retinoid X Receptor (RXR) and binding to 
specific DNA sequences called PPAR responsive elements (PPREs). The general 
composition of  PPREs includes a direct repeat of two hexameric core sequences 
with the consensus AGGTCA which are spaced by one nucleotide (DR1). PPARs bind 
to the 5’  half site of a PPRE whereas RXR binds the 3’ half site. Via the recruitment 
of several coactivators that contain or recruit histone acetylase activity and assist 
with the looping of the PPAR/RXR heterodimer to the basal transcription machinery 
via which transcriptional initiation of PPAR target genes can  occur (88,121). 
The classical approach to identify transcription factor binding sites (TFBS) relies 
on in vitro techniques such as transactivation reporter assays and Electrophoretic 
Mobility Shift Assays (EMSA) that are able to identify specific DNA sequences 
involved in the protein-DNA interaction of transcription factors. The DNA sequences 
obtained using these approaches have been used to create a consensus sequence 
that can act as a template to construct a model for the prediction of transcription 
factor binding sites. Various models have been proposed for predicting DNA 
sequences that can bind PPARs. Most of these models are based on position weight 
matrices (PWM) which assigns weights to nucleotides based on conservation 
between a set of experimentally verified (223). Popular matrix databases such as 
JASPAR, TRANSFAC and MATinspector are all based on these positional weight 
matrices (224). Recently the classifier method showed promising results for PPRE 
predictions. This method is based on experimental obtained DNA binding strengths 
of PPAR-RXR hetrodimers to 39 variants of the traditional DR1 PPRE consensus 
sequence (170). All existing  methods rely heavily on experimentally derived in vitro 
data that lack the genomic likely important for discriminating between a non-active 
binding sites and bona fide PPAR binding sites. This is illustrated by the observation 
that the number of DNA binding sites solely based on computational predictions 
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usually show a very high number of possible binding sites which greatly exceeds the 
number of in vivo found binding sites (225,226). Secondly, several studies compared 
in vivo DNA binding with predicted binding sites based on consensus and showed 
a surprisingly large number of DNA binding sites that do not contain a predicted 
binding site (225,227). For instance, two studies investigating the in vivo binding 
of the androgen receptor and showed that 73-90% of all identified regions did not 
contain the ARE consensus motif (228,229). DNA looping, “piggyback” recruitment, 
assisted binding and histone interaction are proposed mechanisms explaining this 
unexpected phenomenon (181,225). Recent studies investigating the in vivo binding 
of PPARs on a genomic scale have identified many more PPAR DNA interactions 
than genes transcriptionally regulated (84,86) (van der Meer et al., in preparation). 
Clearly, the relation between the predicted DNA binding, in vivo DNA binding and 
expression of a gene is not very well understood. To explore this relationship, we 
compared both ChIP-Chip and expression data to predicted PPARα binding sites 
based on both a PWM for PPAR binding (V$PERO) and the classifier model to 
investigate the relationship between in silico PPRE predictions, in vivo PPARα DNA 
binding and transcriptional gene activation.
Materials and Methods
Cell culture
HepG2 cells were cultured as previously described (van der Meer et al., in 
preparation). The day prior to experiments, cells were split. The following day, cells 
were harvested after 2 h of PPARα agonist GW7647 treatment. Cells used for gene 
expression analysis were harvested after 6 h of agonist incubation.
ChIP-chip 
Chromatin immunoprecipitation (ChIP) was performed as described previously 
(129). In short, after PPARα agonist incubation, DNA-protein interactions were 
fixed by  10 minutes 1% formaldehyde treatment, followed by lyses of the cells. 
Chromatin was sonicated to obtain DNA fragments with and sizes between 500-
1000 bp. PPARα-DNA complexes were isolated using anti-PPARα antibodies (sc-
9000, Santa Cruz Biotechnologies). Control samples were obtained by incubating 
chromatin extracts with normal serum IgG (sc-2027, Santa Cruz Biotechnologies). 
Immunopreciptated chromatin was decrosslinked and DNA purified with a 
GeneChIP Clean-up module (Affymetrix). To obtain sufficient DNA for hybridization, 
purified ChIP DNA was amplified and reamplified with the WGA (re)amplification kit 
(Sigma-Aldrich). Amplified DNA was fragmented with DNAse I to approximately 50 
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bp fragments. The fragments were biotinylated according to Affymetrix instructions. 
Biotinylated DNA fragments were hybridized to the Human Promoter 1.0R Arrays 
(Affymetrix). Arrays were washed and scanned according to instructions from 
manufacturer. All Chip-chip experiments were run in quadruplicate.
Affymetrix microarray CEL files were acquired and normalized using the Model-based 
analysis of tiling-arrays (MAT) algorithm (159). MAT also provided identification of 
PPARα binding regions induced by agonist treatment. Tiling-array probe intensities 
from ChIP performed on HepG2 cells treated for 2 h with GW7647 were compared 
with probe intensities from control IgG ChIP samples . The analysis was performed 
with a MAT score with a p-value of 7.66 x10-3 which was based on MAT scores found 
for promoters of several known PPARα target genes previously (van der Meer et al., 
in preparation). The human NCBIv36 (hg18) was used as a mapping file. Parameters 
used for MAT analysis include a MaxGap of 400 bp and a Bandwidth of 400 bp.
Transcriptomics
Transcriptomics analysis was performed as previously described (van der Meer et 
al., in preparation). Briefly, HepG2 cells were treated with PPARα agonist GW7647 
for 2 and 6 hours. Total RNA was extracted from HepG2 cells using TRIzol reagent 
(Invitrogen) and subsequently purified using the SV Total RNA Isolation System 
(Promega) and appropriate quality was checked before used for cRNA synthesis. 
Five micrograms of RNA were used for one cycle cRNA synthesis (Affymetrix). 
Hybridization, washing and scanning of Affymetrix human genome 133 2.0 plus arrays 
was carried out according to standard Affymetrix protocols. Obtained microarray 
CEL files were processed using packages from the R/Bioconductor project. Arrays 
were normalized with quantile normalization and expression levels of probe sets 
were calculated using the Robust Multichip Average (RMA) method. Differentially 
expressed probe sets were identified using IBMT and genes were considered to be 
significantly changed when the IBMT q-value was < 0.05 and fold-change > 1.2. All 
gene expression analysis by transcriptomics was performed in triplicate.
Characterization of PPARα binding regions
Overlapping regions between two Chip-chip experiments were identified using the 
Galaxy tools (http://main.g2.bx.psu.edu/) (230). The minimum criteria for overlapping 
binding regions was set at 500 bp. Linking of the ChIP peaks to adjacent genes 
was made using the Genomatix tool RegionMiner. Genes with the shortest distance 
to the enriched binding site were selected and compared to transcriptomics data. 
Chip-chip peaks were scanned for the presence of PPAR binding motifs using 
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both the Genomatix model V$PERO as well as the PPAR classifier model. Also for 
identification of overrepresented combinations of transcription factor binding sites 
within a set of PPARα binding sites, the Regionminer tool of the Genomatix package 
was used. For identification of new TF modules the software tool FrameWorker was 
used (160). A minimal presence of a module in the binding regions studied was set 
at 10% and distance bandwidth variation between the motifs was set at maximal 75 
bp. By using ModelInspector, selected PPARα binding regions were scanned for 
the presence of identified modules. As a control, we obtained approximately 77,000 
human promoter regions present in the Genomatix promoter database and selected 
the regions that were in the 1kb-1.5kb range, which corresponds with the size of 
ChIP fragments. A two-proportion z-test to analyze significant enrichment of modules 
was used. Samples with p-values values below 0.05 were considered significantly 
different.
De novo motif analysis
A de novo DNA motif analysis was performed using selected binding regions and 
loaded into the MEME tool (http://meme.sdsc.edu/meme4_1/cgi-bin/meme.cgi). 
Lengths for output motifs was varied between 12 and 18 bp. PWMs of enriched output 
motifs were compared to existing motif matrixes available in either the TRANSFAC 
or the JASPAR database by using the STAMP tool (http://www.benoslab.pitt.edu/
stamp/index.php).
Results
To investigate the DNA binding dynamics of PPARα, in vivo Chip-chip analysis 
was performed on HepG2 cells at basal conditions and after 2 hours PPARα 
agonist GW7647 induction. Three predominant PPAR binding profiles were found: 
occupancy of PPARα at basal conditions that disappeared after PPARα activation, 
PPAR binding observed only after 2 hours agonist addition and a binding profile that 
showed enriched PPARα binding at both basal conditions and after 2 hours PPARα 
agonist induction (Figure 1A). Approximately half of the PPAR binding regions that 
were identified at basal conditions and about half of the PPAR binding regions found 
after 2 hours ligand induction were commonly enriched, indicating that some DNA 
regions are bound by PPARα independently of PPARα agonist activation (Figure 
1B).
Genes located closest to the identified PPARα binding regions were compared with 
transcriptionally regulated genes after 6 hours of PPARα activation. As the number of 
PPARα binding regions greatly exceeds the number of differentially regulated genes, 
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only a fraction (between 1%-2%) of the binding sites can be linked to transcriptionally 
regulated genes. Interestingly, transcriptionally downregulated genes showed a 
significantly lower association with PPARα binding sites that were enriched after 
2 hours PPARα activation and binding regions that were enriched at basal and 
after PPARα stimulation when compared to binding regions only enriched at basal 
conditions or the control regions (Figure 2A). In contrast, none of the binding profiles 
showed a significant change in association to transcriptionally upregulated genes 
when compared to control regions. To analyze the relation between in vivo PPARα 
binding dynamics and predicted binding based on sequence, regions with the various 
binding profiles were scanned for the presence of PPREs based on the prediction 
model of Genomatix (V$PERO) as well as the classifier model with two different 
stringencies (score > 1 and score > 20). For both methods very similar percentages for 
predicted binding sites were found between the three PPARα binding profiles (Figure 
2B). However, between the two methods there were clear differences. The presence 
of predicted PPREs using the V$PERO model showed approximately double the 
amount of predicted binding sites compared with the classifier method at its lowest 
stringency. Furthermore the classifier method showed even further reduction of 
identified PPAR binding sites when using the higher threshold (>20). To investigate 
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Figure 1: Enrichment DNA binding by PPARα at basal conditions and after 2 hours agonist induc-
tion. (A)Three typical DNA binding patterns at basal and after 2 hours agonist stimulation were identified 
by combinding  ChIP-Chip data. The binding patterns showed enriched DNA binding upon 2 hours agonist 
stimulation (2hIgG only), only enriched DNA binding at basal conditions (0hIgG only) or a pattern showing 
DNA binding at both time points (Both). (B) Venn diagram showing the occurrence of the identified binding 
patterns within the compared ChIP-Chip data. 
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the prediction model that performs best at the promoter regions of regulated genes, 
the regions linked to regulated genes were scanned with the respective models. 
Predicted PPARα binding sites by the classifier model showed approximately twice 
the number of predicted binding sites in regions that were transcriptionally upregulated 
and showed enriched PPARα binding only after 2 hours PPAR activation compared 
to predicted binding sites in control promoter regions (Figure 2C). In contrast, the 
V$PERO predicted sites in promoter regions of upregulated genes only showed a 
very modest increase in presence compared to control binding sites. Although the 
V$PERO model predicts approximately the same number of binding sites in promoter 
regions of upregulated genes as the classifier algorithm, the latter showed to be 
more selective for binding sites linked to transcriptionally upregulated genes. The 
PPARα binding regions linked to upregulated genes with PPARα binding specifically 
seen after two hours agonist induction and containing a predicted PPRE based on 
the classifier method were further analyzed. Since the cooperation of transcription 
factors is an important aspect of specific gene regulation, these selected regions 
were scanned for overrepresentation of combinations of transcription factor binding 
sites together with a V$PERO site, using Regionminer of Genomatix because 
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Figure 2: Comparison between the PPARα DNA binding patterns, gene expression and in silico 
predicted PPARα DNA binding. (A) The percentage of  transcriptional upregulated or downregulated 
genes associated with a PPARα DNA binding profile. (B) Occurrence of a predicted PPARα binding site 
based on either the V$PERO or the Classiefier algorithm in all identified PPARα binding regions. (C) Oc-
currence of predicted binding sites in identified binding regions associated with transcriptionally changed 
genes.
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such a tool is not available for the classifier matrix. Regions within the selected 
group showed the highest enrichment of V$PERO together with binding sites of 
the transcription factor families: Fork head domain factors (FKHD), Nuclear factor 
of activated T-cells (NFAT), Bromodomain and PHD domain transcription factors 
(BPTF), Ccaat/Enhancer Binding Protein (CEBP) and  Human and murine ETS1 
factors (ETSF). Enrichment of these combinations of transcription factor binding 
sites was not found significant in unstimulated cells (Figure 3A). Interestingly, CEBP 
has been found to be overrepresented together with PPARγ previously in mouse. 
In addition, a de novo motif analysis was performed with the selected regions that 
showed enriched binding, were upregulated after 2 hours and contained a PPRE 
predicted with the classifier method. Among the identified motifs, two motives showed 
a PWM  similar to either the PPARα/RXR matrix in the TRANSFAC database or the 
CEBP matrix in the JASPAR database (Figure 3B). Since PPAR binding elements 
seem to coexist with other transcription factor binding sites, Frameworker was 
used to identify specific transcription factor modules composed of binding sites of 
transcription factors that show similar orientation and distance to each other. The 
transcription factor binding sites that were overrepresented together with V$PERO 
were selected and the combinations scanned for significant modules. Again this 
analysis was performed on the selected PPARα binding regions based on binding 
pattern and linkage to expression data. No significant module was found for BPTF 
in combination with  the PERO matrix, however significant modules composed of 
2hIgG upregulated + predicted PPRE2hIgG upregulated + predicted PPRE
Modules with V$PERO Over rep (genome) Z-Score 
Over rep
(promoters) Z-Score 
V$FKHD-V$PERO 2.46 7.05 3.95 11.27
V$NFAT-V$PERO 2.56 4.92 3.17 6.17
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V$CEBP-V$PERO 3 4.55 4.14 6.11
V$ETSF-V$PERO 2.16 4.4 1.81 3.34
0hIgG downregulated + predicted PPRE
V$FKHD-V$PERO 1.25 1.56 2.01 5.04
V$NFAT-V$PERO 0.93 -0.4 1.15 0.46
V$BPTF-V$PERO 0.6 -0.99 0.93 -0.44
V$CEBP-V$PERO 0.71 -1.06 0.98 -0.23
V$ETSF-V$PERO 0.83 -0.96 0.7 -1.79
Modules with V$PERO Over rep (genome) Z-Score 
Over rep
(promoters) Z-Score 
A B
PPARalpha-RXRalpha  3.5E-04
(TRANSFAC)
1
2
0
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
bi
ts
Ddit3-Cebpa  5.2788e-04
(JASPAR)
1
2
0
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
bi
ts
Figure 3: Transcription factor module analysis in PPARα binding regions. PPARα binding regions 
associated with transcriptionally regulated genes which contained a predicted PPRE, based on the clas-
sifier algorithm, were scanned for transcription factor modules. (A) Using the Regionminder tool, several 
combinations with the V$PERO site were identified. A z-score > 2 is considered significantly enriched.(B) 
De novo motif analysis using MEME in combination with the STAMP tool revealed a motif with similarities 
to the TRANSFAC motif for PPARα-RXR as well as a JASPAR motif with similarities to the CEBP/α motif. 
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PERO together with NFAT, CEBP, FKHD and ETSF were found. Interestingly, the 
modules PERO-NFAT and CEBP-PERO showed significant higher presence in the 
regions linked to upregulated genes with a binding profile corresponding to specific 
PPARα binding only after two hours agonist induction compared to the other selected 
PPARα binding profiles as well as the control regions. The other modules do not 
seem to link to a specific binding pattern (Figure 4A).  Previously, the module NFAT-
CEBP was identified to play an important role in the activation of various genes, 
including PPARγ (231). Therefore the occurrence of this known module, composed 
of these two TFBS was investigated. As shown in figure 4B, the NFAT-CEBP module 
is enriched in all three groups of PPARα binding regions compared to control regions. 
Within these regions this module is significantly more present in regions that are 
linked to upregulated genes and showed specific enrichment of binding after 2 hours 
of PPARα agonist induction or in the regions that showed enriched binding at basal 
conditions and after two hours PPARα induction. Involvement of the NFAT-CEBP 
module in cooperation with PPARα binding might be one mechanism for PPARα 
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Figure 4: Occurrence  of the identified modules in PPARα binding regions. (A) Enrichment of the 
identified modules in specific PPARα binding regions that were linked to transcriptionally changed genes 
. (B) The occurrence of an additional identified module that does not include an V$PERO.
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mediated transcriptional gene regulation. 
Discussion
PPARα is an important player in the regulation of fatty acid metabolism. The location 
in the genome where PPARα binds is an important factor in PPARα mediated  gene 
regulation. For prediction of a PPAR binding site in the genome, position weight 
matrixes were created which are based on the consensus sequence derived from 
previously reported functional binding sites. The problem with such matrixes is the 
high number of false positives found at such a high degree that the futility theorem 
was proposed (232), essentially meaning that almost all of the predicted binding 
sites are not functional. To select true binding site of PPARs in the genome, several 
studies identified in vivo transcription factor binding sites using ChIP-Chip or ChIP-
seq including for PPARγ and PPARα (84,86,87,233). Interestingly, the amount 
of binding sites still exceeds the number of genes regulated by the transcription 
factor, implying that binding of the transcription factor to the genome is by itself not 
sufficient for the initiation of transcription of a target gene. Various other factors may 
be involved, including DNA/histone methylation and acetylation, which may influence 
the three dimensional structure as well as the interplay between transcription factors 
via so called cis-regulatory modules. Furthermore, initiation of gene transcription 
may not necessarily results in a change in gene expression, and therefore ChiP-
Chip for Pol II may be a more accurate comparison for in vivo PPARα DNA binding. 
To further explore the relationship between in vivo PPARα DNA binding, predicted 
PPARα DNA binding and actual regulated genes by PPARα, we compared data sets 
that analyze these three events. 
Using ChIP-Chip data at basal and after 2 hours PPARα agonist treatment, three 
binding profiles for PPARα were identified. We linked the PPARα binding regions 
of the separate profiles to the closest gene on the genome and compared these 
genes with transcriptionally regulated genes after 6 hours PPARα activation. 
Although a relation between binding pattern and upregulated genes was not found, 
genes downregulated contained a significant lower number of regions that had a 
PPARα binding profile corresponding to binding at both basal and after two hours 
agonist induction as well as regions that showed PPARα binding only after agonist 
treatment. This finding might indicate a negative correlation between binding of 
PPARα and transcriptional downregulation, possibly meaning that PPARα binding 
is seen more often either near unregulated genes or transcriptionally upregulated 
genes. The same groups of binding regions based on PPARα binding profile 
was scanned for the presence of a PPRE based on two different PPARα binding 
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prediction algorithms. Very similar numbers of predicted binding sites were found for 
the three binding profiles, indicating that a binding profile on its own is not associated 
with higher prediction of PPREs. However the classifier method predicted significant 
lower numbers of PPARα binding sites, implying that the classifier method has 
more stringent criteria for PPRE prediction than the PWM based prediction matrix 
of genomatix (V$PERO). For both methods the predicted numbers of binding sites 
for PPARα was higher than the number of genes transcriptionally regulated, which 
may support the idea that PPARα binding alone is insufficient for the activation 
of a target gene. The performance of the respective models in regions that were 
linked to transcriptionally regulated genes was investigated. Regions that were 
linked to upregulated genes and had enriched PPARα binding only after two hours 
activation, showed approximately a twofold increase of predicted PPREs compared 
to all regions, using the classifier method, whereas the V$PERO site was only 
slightly enriched in all regions linked to transcriptional regulated genes. These 
results may indicate that the classifier method is more selective for PPREs linked 
to transcriptionally upregulated genes, however the V$PERO matrix overall better 
represents the binding regions found in vivo, although most of the in vivo binding 
regions did not link to a regulated gene and possibly also include regions that do 
not interact directly  with PPARα. The binding group linked to upregulated genes 
with a binding profile only after 2 hours of PPARα activation was further analyzed 
for possible enriched transcription factor modules. Several enriched transcription 
factor binding site modules were identified. Cooperation between PPAR and CEBP 
has been proposed recently for PPARγ in mice (86). Since we found the CEBP-
PERO module enriched in the selected binding sites, this module might be involved 
in PPARα signaling as well.. Furthermore, other modules with the V$PERO motif 
that may play some part in PPAR mediated gene activation were found, including 
PERO-NFAT, FKHD-PERO and PERO-ETSF. In addition, the previously reported 
module NFAT-CEBP (231) was enriched in regions linked to upregulated genes. 
Interestingly, this module has been associated with the transcriptional regulation of 
PPARγ itself. Possibly this module also plays a role together with PPARα in the 
regulation of PPARα target genes. In conclusion, our data show that PPARα binding 
in vivo and predicted PPARα binding site overlap depends mainly on the prediction 
model used. Whereas the V$PERO module showed high overlap with the in vivo 
found binding sites, the classifier method predicted more specifically binding sites 
linked to expressional upregulated genes. Both models however predicted more 
binding sites than genes regulated, indicating factors other than DNA sequence 
are involved in transcriptional regulation mediated by PPARα. Furthermore, various 
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transcription factor binding site modules emerged from our data that may have a 
function in PPARα mediated gene regulation.
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Since the discovery of the peroxisome proliferators activated receptors (PPARs) in 
the early 90s, much research has been performed on these nuclear receptors. These 
investigations have clearly established  the PPARs as very important transcription 
factors  involved in the regulation of lipid metabolism and storage as well regulation 
of inflammation and immunity. Based on this acquired knowledge,  PPAR targeted 
pharmacological therapeutics have been developed for the treatment of metabolic 
dysfunctions such as dyslipidemia and diabetes. Relative to the amount of research 
dedicated to the physiological aspects of PPAR functions, research focused on 
the basic mechanisms of PPARα action has been limited and consequently many 
aspects of the molecular dynamics of PPAR action is not well understood. To expand 
our knowledge regarding the molecular action of PPARα, the primary aim of the 
research described in this thesis was to analyze the global molecular dynamics of 
the nuclear receptor PPARα using genomic, proteomic and expressional profiling 
tools. 
Thanks to the recent introduction of various large scale screening techniques such 
as mass-spectrometry, expression microarrays and genomic tiling arrays, it has 
become possible to investigate proteins, mRNA and DNA binding in a global manner. 
Experiments described in this thesis depend heavily on these new techniques. 
Mass-spectrometry was utilized for identification of potential new PPARα protein 
interactions (Chapter 2). Tiling arrays were used to obtain a PPARα DNA binding 
profile at all promoter regions in the human genome  (Chapter 3). Expression 
microarrays were used for identification of mRNA expressional changes upon 
PPARα activation (Chapter 4). Finally, the results of gene expression microarrays, 
DNA binding and predicted (in silico) DNA binding were compared (Chapter 5). 
As the physiological role of PPARα is mainly focused in the liver, we sought for an 
appropriate liver cell model. The most commonly used human liver cell model is the 
hepatoma HepG2 cell line.  To investigate the suitability of this cell line for studying 
PPARα dependent gene regulation, a comparison between this HepG2 cells and 
isolated human primary hepatocytes was made .  Although we showed that the 
HepG2 model cell line markedly differ from primary human hepatocytes with respect 
to the genes activated upon PPARα agonist stimulation (Chapter 4), the lack of an 
alternative better human liver cell lines has made HepG2 cells the best choice for 
human liver research especially considering the amount of cell material required and 
the techniques used. However, interpretation of results should be made with caution 
and with the limitations of the HepG2 cell line in mind.
As dynamic protein-protein interactions between transcription factors and coregulatory 
proteins play an vital functional role, we pursued an approach aimed at finding novel 
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protein interaction partners of PPARα. A proteomic approach was applied, using a 
transiently introduced tagged PPARα protein in HepG2 cells. Various nuclear proteins 
that interacted with PPARα could be identified (Chapter 2). Among the identified 
proteins, several proteins were previously characterized to have a functional role 
in the function of transcription factors other than PPARα, either as a coactivator or 
corepressor. None of the identified interacting proteins was previously  linked to 
PPARα regulation,  with the exception of one identified proteins, b-catenin. b-catenin 
was previously shown to interact with PPARγ, which may have an anti-carcinogenic 
function in colon and breast cancer. Furthermore, signaling via the upstream Wnt 
pathway was shown to result in upregulation of PPARγ target genes (140,234). 
Other PPARα interacting proteins identified by others using similar proteomic or other 
experimental procedures, were not found (103). Possibly interaction with b-catenin 
is favored since the HepG2 cell line is a tumor derived cell line where PPARα may 
interact with b-catenin in a similar fashion as with PPARγ. Because of the low 
number of previously identified PPARα interacting proteins as well as the rather 
low specificity of the approach used, we did not pursue these experiments. Future 
improvement in the technique used is required to improve specificity. For instance 
the signal-to-noise ratio of specific interacting proteins compared to total nuclear 
proteins could be achieved by increasing the number of tagged proteins actively 
engaged in transcriptional activity, increasing the number of cells in which such 
activity takes place and improvement of the immuno-purification protocol. Only part 
of these improvements was deemed feasible in the transient activation system in use. 
To investigate DNA occupancy of PPARα in promoter regions, ChIP-Chip technology 
was performed (Chapter 2). Using this technique, over 4000 PPARα binding regions 
were found to be enriched upon agonist stimulation of PPAR. The genes closest to the 
identified DNA binding regions were compared with the mRNA level of these genes. 
Only a fraction of the binding regions could be linked to actual regulated genes (54 
upregulated and 46 downregulated). Previous studies that investigated PPARγ DNA 
binding or DNA binding by other transcription factors, showed a similar discrepancy 
between the number of transcriptionally regulated genes and transcription factor 
DNA binding. The assignment of binding regions to the nearest gene is expected 
to cause a large number of false negatives, since regulation of gene expression is 
frequently achieved via distant regulatory binding sites, which are falsely linked to 
genes located in closer proximity. The high total number of binding regions identified 
relative to the number of regulated genes may have either a biological or technical 
origin. Non-specific PPARα binding fits with a previously proposed “scanning model” 
(88), were PPARα transiently binds to non-specific  DNA  until it finds a bona fide high 
100
Chapter 6
affinity PPRE. However, the extensive size and density of the genome might become 
problematic for a transcription factors if a fast response to a stimuli is required and 
the whole genome has to be scanned to find bona fide response elements. To tackle 
this problem, some interesting models have recently been proposed (181). In the 
classical view, bound transcription factors have an individual role at binding sites 
within the genome resulting in transcriptional activation of a nearby located target 
gene. This may be the case at a subset of the genomic locations.  However, the 
same factor may have a different “community” role at other locations in the genome. 
For instance, a set of several transcription factors may bind to a genomic location 
to recruit  histone acetyltransferases or histone methyltransferases to secure an 
open chromatin structure for another transcription factor that is responsible for 
transcription of the gene located in this region (181). Furthermore, a function for 
transcription factors as “bumper” proteins was proposed. These bumper proteins 
may be involved in the shortening of genomic scanning of a transcription factor. As 
a transcription factor searches for a response element, it may interact shortly with 
the DNA at non-specific genomic sites from which it may start scanning for a specific 
high affinity binding site. Transcription factors serving as a bumper proteins bound 
at DNA will interfere with scanning of an activated transcription factor in the wrong 
direction or at the wrong location and thereby minimize the time delay caused by 
extensive scanning of a transcription factor. These models imply a very dynamic 
and complex mechanism for transcriptional activation, where transcription factors 
can have multiple roles depending on the genomic region and interplay with other 
available transcription factors in the cell. Our findings that a PPARα binding element 
is enriched in regulated genes with binding elements of either TATA binding protein 
(TBP) or STAT (Chapter 3) as well as the modules found in chapter 5 may be just 
one small part of this complex and dynamic regulatory network.
Technically, chromatin immuno-precipitation has some inherent fallbacks which 
may account partially for an overestimation of transcription factor binding regions. 
Antibodies used for the precipitation of PPARα may have some degree of 
crossreactivity, raising the number of binding sites unspecific for PPARα.  However a 
good alternative for the isolation of proteins bound to DNA is currently  not available. 
Techniques based on the isolation of the DNA using tags or oligonucleotides, coupled 
with mass-spectrometry were proposed  that may be developed in the future and 
may provide a good alternative for investigation of specific DNA sites (73). In addition 
to the crossreactivity problem with antibodies, the crosslinking step to covalently 
bind PPARα to the DNA, which takes several minutes, may give rise to nonspecific 
crosslinking of PPARα to DNA sites that were not specifically bound. To circumvent 
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this problem, laser based crosslinking that instantly crosslinks proteins to DNA is a 
promising alternative (235).
In the last chapter (Chapter 5), DNA binding and transcriptomics datasets were 
compared with two algorithms that predict DNA binding by PPAR. We concluded that 
the overlap between actual binding regions and predicted PPAR binding sites heavily 
depend on the prediction model used. Although we found predicted PPREs in up to 
70% of the in vivo found PPARα binding regions with the V$PERO matrix, this was 
not enriched over random promoter regions. Similarily the more stringent classifier 
matrix was not enriched over control promoter regions.  Further comparisons showed 
very little overlap between PPRE prediction and gene expression changes upon 
PPARα activation, although the classifier seemed to perform better in predicting 
PPREs in promoter regions of regulated genes. Thus, prediction of DNA binding 
by PPAR based on sequence alone poorly correlates with transcriptional activation 
of the gene near the predicted PPRE. In vivo identified regions without a predicted 
PPRE may have been bound by PPARα in an indirect manner, for instance via 
looping or protein-protein interaction with other DNA binding proteins. Also technical 
limitations encountered with ChIP may be responsible for an overestimation of 
PPARα DNA binding as discussed above. Furthermore, limitations of the cell type 
used with respect to expression of PPARα target genes (Chapter 4) may give rise to 
a reduced correlation between PPARα binding and regulation of gene expression. 
Previous attempts to compare transcriptionally regulated genes by PPARα with 
predicted PPARα DNA binding at all mouse promoter regions also found a very poor 
correlation between regulation of gene expression and predicted PPARα binding 
(Sanderson et al, unpublished). These results indicate clearly that predicting target 
genes for a given transcription factor solely based on DNA sequence is very risky and 
would need additional evidence. More factors need to be considered in the genomic 
context in vivo to be able to predict a genomic location regulated by PPARα. Spatial 
factors may play an important role in the extremely dense environment in the nucleus, 
especially when very large protein complexes like the transcriptional complex have to 
bind. Therefore, predicted DNA binding sites that are found at genomic locations that 
are part of the heterochromatin may never be accessed by PPARα. In this context, 
proteins such as histone acetyltransferases and DNA helicases possibly play an 
important role by making the DNA more accessible for larger protein complexes 
that are required to activate genes. Possibly, the previously mentioned “community” 
role of transcription factors may provide the recruitment of proteins responsible for 
opening the chromatin structure. Interestingly, we found several proteins involved in 
the histone modification process within the isolated PPARα protein complex.  
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In the comparisons described in chapter 3 and 5, the the proteomics data was not 
included because PPARα protein-protein interactions were considered to act on a 
different, more upstream level when compared to the DNA interaction and gene 
expression studies. In other words, PPAR binding to the promotor of a particular gene 
and actual change in mRNA level of that same gene is expected to be much stronger 
correlated in comparison with the binding of a cofactor to PPARα and the expression 
of that coregulator gene. Surprisingly, we did identify two genes that emerged in all 
datasets (F5 and MNL2). Possibly these proteins are involved in a positive feedback 
loop of PPARα via protein-protein interaction and are transcriptionally regulated 
by PPARα, however these proteins have not been identified as transcriptional 
regulators previously. Statistically expected overlap between the three data sets is 
2.2, suggesting the found overlap of two genes has a high chance of being random. 
However, further analysis using functional assays will be required to decide whether 
this represents a meaningful subset of PPAR targets and points to an interesting 
link between protein-protein interaction, protein-DNA interaction and transcriptional 
regulation.
As illustrated in this thesis,  “omics” techniques are a very valuable toolset to 
gain further insight into the mechanism  and consequences of PPARα activation. 
Since the amount of data generated is very extensive, -omics approaches  usually 
provide a global picture, which makes strong mechanistic conclusions often difficult. 
Therefore, additional research is in many cases necessary to further elucidate 
the mechanisms responsible for the global changes observed with omics tools. 
Nevertheless with continued development of new and improved techniques backed 
by strong bioinformatical support, omics is expected to remain one of the key tools 
available within biology.
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Door de toenemende welvaart in de westerse wereld komen bepaalde 
gezondheidsproblemen zoals obesitas (overgewicht) in stijgende mate voor. Obesitas 
gaat vaak gepaard met afwijkingen in de stofwisseling resulterend in verhoogde 
glucose, cholesterol en tri-glyceride waarden in het bloed. Deze verhoode waarden 
worden geassocieerd met een verhoogd risico op de ontwikkeling van ziekten zoals 
hart- en vaatziekten en type 2 diabetes. Een van de processen die mogelijk verstoord 
zijn bij obesitas is de verbranding van vet. Door de bestudering van de fundamentele 
moleculaire mechanismen die betrokken zijn bij de vetverbranding ontstaan mogelijk 
aangrijpingspunten voor de behandeling of preventie van obesitas
Eén van de eiwitten die betrokken is bij de regulatie van de vetverbranding is de 
nucleaire receptor “Peroxisome Proliferator-Activated Receptor alpha” (PPARα). 
PPARα  bevindt zich in de  celkern en fungeert als transcriptie factor die geactiveerd 
wordt door binding van onverzadigde vetzuren. PPARα bindt aan het DNA en 
verhoogt in geactiveerde status de transcriptie van genen die coderen voor 
verscheidene enzymen en andere eiwitten die ervoor zorgen dat de vetzuren in de 
cel weer worden afgebroken, zodat de energie huishouding in balans blijft.
Het in dit proefschrift beschreven onderzoek gaat in op verschillende aspecten met 
betrekking tot de werking van PPARα. Ten eerste is er onderzocht welke eiwitten er 
samenwerken met PPARα om te komen tot de transcriptie van een gen. Ten tweede 
is onderzocht waar op het DNA PPARα bindt en of deze binding te relateren is aan 
de expressie van genen die dicht bij de PPARα bindings plaats liggen. Daarna is 
gekeken in welke mate het mogelijk is om binding van PPARα op het genoom te 
voorspellen aan de hand van specifieke DNA codes. Ten slotte is er een vergelijking 
gemaakt tussen genen die door PPARα geactiveerd worden in primaire humane 
lever cellen en in de humane lever cellijn HepG2.
PPARα is op zichzelf niet in staat om een gen tot expressie te laten komen. Hiervoor 
moeten er nog zogenaamde coactivatoren aan PPARα binden waardoor er een 
eiwit complex ontstaat dat wel in staat is om de aflezing van een gen te activeren. 
Het is nog niet helemaal bekend welke coregulatoren er allemaal betrokken zijn bij 
deze activering.  Met behulp van de immunoprecipitatie techniek kunnen eiwitten 
worden geïsoleerd die een interactie aangaan met een specifiek eiwit dat als lokaas 
fungeert. Deze eiwitten kunnen vervolgens met behulp van massa-spectrometrie 
geïdentificeerd worden. Deze technieken hebben we toegepast om de eiwitten te 
identificeren die een interactie aangaan met PPARα, resulterend in verscheidene 
eiwitten die een mogelijke rol spelen in regulatie van genexpressie door PPARα.
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Om te onderzoeken op welke plekken op het DNA geactiveerd PPARα bind, hebben 
we een ChIP-Chip experiment gedaan. Deze techniek combineert chromatine 
immunoprecipitatie (ChIP) met een DNA chip. Met behulp van een ChIP is het 
mogelijk om DNA fragmenten van ongeveer 1000 baseparen  te isoleren waaraan 
PPARα gebonden is. Door deze fragmenten te hybridiseren aan een promotor tiling 
microarray kan er een profiel gemaakt worden van PPARα binding in alle humane 
promotor regio’s op het genoom. Meer dan 4000 DNA regio’s zijn op deze manier 
geïdentificeerd, inclusief de promotor regio’s van verscheidene eerder beschreven 
PPARα genen. Door de genen in de gevonden regio’s te vergelijken met PPARα 
gen expressie data hebben we een relatie gevonden tussen genen die verminderde 
expressie vertoonden en PPARα bindings regio’s die een bindings element bevatten 
voor bepaalde andere transcriptie factoren, de STATs. Deze bevinding  is interessant 
omdat de STATs een rol spelen in ontstekingsreacties waarvan bekend dat PPARα 
deze kan onderdrukken. Mogelijk wordt de expressie  van een STAT geactiveerd gen 
verhinderd door de binding van PPARα op dezelfde plek. Ook werd er een verband 
gevonden tussen de transcriptie factoren PPARα en TBP, PPARα en C/EBPα en 
mogelijk  PPARα and SREBP in regio’s geassocieerd met genen die verhoogde 
expressie vertonen. Mogelijk spelen deze transcriptie factor combinaties een rol in 
de specifieke activering van genen door PPARα.
Om te kijken wat de relatie is tussen de binding van PPARα op het DNA, PPARα 
geïnduceerde genexpressie en voorspelde DNA binding door PPARα hebben 
we deze data met elkaar vergeleken. Uit deze vergelijking blijkt duidelijk dat de 
hoeveelheid plaatsen waar PPARα bind op het genoom groter is dan de hoeveelheid 
genen die geactiveerd worden. Dit duidt er op dat een binding op het DNA door 
PPARα in de meeste gevallen niet betekent dat hierdoor een dichtbij gelegen gen 
geactiveerd wordt. Mogelijk heeft PPARα op deze plekken een andere onbekende 
rol. Ook blijkt uit deze vergelijking  dat het voorspellen van binding op grond van 
enkel DNA sequentie geen verrijking gaf van PPARα bindings plekken in de PPARα 
bindings regio’s geïdentificeerd met ChIP-Chip ten opzicht van willekeurige promotor 
regio’s. Wel geef een voorspellingsmethode op grond van sequentie een verrijking 
in de regio’s geassocieerd met genen die verhoogd tot expressie komen. Mogelijk 
is deze methode bruikbaar voor het identificeren van nieuwe genen die gereguleerd 
kunnen worden door PPARα.
Als laatste zijn de gen expressie patronen na activering van PPARα in de lever cellijn 
HepG2 vergeleken met die in humane primaire hepatocyten. Uit deze vergelijking 
blijkt dat de HepG2 cellijn de bekende functies van PPARα maar in beperkte mate 
reflecteert ten opzichte van primaire hepatocyten. Verschillende bekende PPARα 
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genen die wel tot expressie komen in de primaire hepatocyten geven geen response 
in de HepG2 cellijn. Daarom is het verstandig om bij gebruik van de HepG2 cellijn 
de resultaten kritisch te benaderen en indien mogelijk te kiezen voor primaire 
hepatocyten. Maar omdat er geen goede alternatieve humane lever cellijn die 
gemakkelijk te verkrijgen is  blijft de HepG2 lijn de meest voor de hand liggende 
keuze als model voor PPARα activatie in humane lever cellen.  
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Na 4 jaar (en een beetje) werk is het er toch van gekomen: mijn proefschrift is af! 
Natuurlijk was dit nooit gelukt zonder de hulp en steun van velen. Sommige heel 
direct en andere waren meer op de achtergrond betrokken bij het tot stand komen 
van dit proefschrift.  
Allereerst wil ik mijn promotoren, Sacco en Michael bedanken voor de mogelijkheid 
om als aio aan het werk te gaan binnen de vakgroepen Biochemie en Humane 
voeding. Sacco, het eerste jaar was je eigenlijk ook mijn directe begeleider en 
in die tijd heb ik veel geleerd, maar ook later, toen je mijn onderzoek meer van 
afstand volgde, was je input nog steeds van veel betekenis. Michael, bedankt voor 
de adviezen die je gaf tijdens de vrijdagochtend meetings, ook hier heb ik veel aan 
gehad. 
Sander, nadat ik naar het erfelijkheidsleer gebouw verhuisde, omdat ik me  ging 
richten op de microarray technieken, werd jij meer mijn directe begeleider. Ik 
waardeer het erg dat je me vaak veel vrijheid hebt gegeven en waar nodig duidelijke 
adviezen en richting hebt gegeven. De manier waarop jij goed en pragmatische 
je onderzoek doet respecteer ik zeer. Maar ook je humor heb ik altijd erg kunnen 
waarderen. 
Ik wil ook de mensen bedanken die mij in het eerste jaar bij biochemie hebben 
geholpen. In het bijzonder wil ik danken: Sjef, bedankt voor de LC-MS metingen. 
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